Modified TGF-beta oligonucleotides

ABSTRACT

The invention refers to an oligonucleotide consisting of 10 to 20 nucleotides of selected regions of the TGF-beta1, TGF-beta2 or TGF-beta3 nucleic acid sequence, which comprises modified nucleotides such as LNA, ENA, polyalkylene oxide-, 2′-fluoro, 2′-O-methoxy and/or 2′-O-methyl modified nucleotides. The selected regions are preferably the region of nucleic acid no. 1380 to 1510, no. 1660 to 1680, no. 2390 to 2410, or no. 2740 to 2810 of the TGF-beta2 nucleic acid sequence of SEQ ID NO. 1, specific regions of the TGF-beta1 nucleic acid sequence of SEQ ID NO. 149, or specific regions of the TGF-beta3 nucleic acid sequence of SEQ ID No. 267. The invention further relates to pharmaceutical compositions comprising such oligonucleotide, wherein the composition or the oligonucleotide is used in the prevention and/or treatment of a malignant and/or benign tumor, an immunologic disease, fibrosis, glaucoma, etc.

CROSS REFERENCE TO RELATED APPLICATIONS

The invention is a divisional and claims priority to U.S. application Ser. No. 14/780,043, filed on Sep. 25, 2015, which is a national phase of PCT/EP2014/056221, filed on Mar. 27, 2014, which claims the benefit of priority to European Patent Application No. 13199826.2, filed Dec. 30, 2013, European Patent Application No. 13173078.0, filed Jun. 20, 2013, and European Patent Application No. 13161474.5, filed Mar. 27, 2013, the entire contents of each of which are hereby incorporated in total by reference.

SEQUENCE LISTING

This application incorporates by reference the Sequence Listing contained in an ASCII text file named “362346_00046 SeqList.txt” submitted via EFS-Web. The text file was created on Jan. 29, 2018, and is 90 kb in size.

BACKGROUND OF THE INVENTION

This invention is directed to oligonucleotides consisting of 10 to 20 nucleotides of elected regions of the TGF-beta2 nucleic acid sequence, alternatively elected of the TGF-beta1 or TGF-beta3 nucleic acid sequence, which comprise modified nucleotides such as LNA, ENA, polyalkylene oxide-, 2′-fluoro, 2′-O-methoxy and/or 2′-O-methyl modified nucleotides.

Transforming growth factor beta (TGF-beta) is a protein that controls proliferation, cellular differentiation, and other functions in most cells. It is a type of cytokine which plays amongst others a role in immunity, cancer, heart disease, diabetes, Marfan syndrome, Loeys-Dietz syndrome, Parkinson's disease, and AIDS.

TGF-beta is a secreted protein that exists in at least three isoforms (TGF-beta1, TGF-beta2 and TGF-beta3) encoded by different genes but sharing strong sequence and structure homologies. TGF-beta acts as an antiproliferative factor in normal epithelial cells and at early stages of oncogenesis. However, later in tumor development TGF-beta can become tumor promoting through mechanisms including the induction of epithelial-to-mesenchymal transition (EMT), a process that is thought to contribute to tumor progression, invasion and metastasis (see “Glycoproteomic analysis of two mouse mammary cell lines during transforming growth factor (TGF)-beta induced epithelial to mesenchymal transition” 7^(th) space.com.2009-01-08. Retrieved: 2009 Jan. 29).

In normal (epithelial) cells, TGF-beta stops the cell cycle at the G1 stage (and stops cell proliferation), induce differentiation, or promote apoptosis. When a cell is transformed into a cancer cell, TGF-beta no longer suppresses cell proliferation, which is often the result of mutations in the signaling pathway, and cancer cells proliferate. Proliferation of stromal fibroblasts is also induced by TGF-beta. Both cells increase their production of TGF-beta. This TGF-beta acts on the surrounding stromal cells, immune cells, endothelial, smooth-muscle cells, and tumor microenvironment (see Pickup et al., “The roles of TGFβ in the tumour microenvironment”, Nature Reviews Cancer (2013), 13: 788-799). Thereby, it promotes angiogenesis, and by suppressing proliferation and activation of immune cells it causes immunosuppression.

TGF-beta1-deficient mice die from cardiac, pulmonary, and gastric inflammation, suggesting that TGF-beta has a vital role in suppressing the activation and proliferation of inflammatory cells. Smad3 is one of the key elements in TGF-beta dependent downstream signaling pathways. Smad3-deficient mice develop chronic mucosal infections due to impairment of T-cell activation and mucosal immunity, suggesting a key role for TGF-beta in these processes. With respect to cancer, the production and secretion of TGF-beta by certain cancer cells suppress the activities of infiltrating immune cells, thereby helping the tumor to escape host immunosurveillance. This immunosuppressive effect may be another important mechanism by which TGF-beta stimulates the growth of late-stage tumors (see Blobe G C et al., May 2000, “Role of transforming growth factor beta in human disease”, N. Engl. J. Med. 342 (18), 1350-1358). TGF-beta also converts effector T-cells, which normally attack cancer with an inflammatory (immune) reaction, into regulatory (suppressor) T-cells, which turn off the inflammatory reaction.

Further, TGF-beta is one of the most potent regulators of the production and deposition of extracellular matrix. It stimulates the production and affects the adhesive properties of the extracellular matrix by two major mechanisms. First, TGF-beta stimulates fibroblasts and other cells to produce extracellular-matrix proteins and cell-adhesion proteins, including collagen, fibronectin, and integrins. Second, TGF-beta decreases the production of enzymes that degrade the extracellular matrix, including collagenase, heparinase, and stromelysin, and increases the production of proteins that inhibit enzymes that degrade the extracellular matrix, including plasminogen-activator inhibitor type 1 and tissue inhibitor of metalloprotease. The net effect of these changes is to increase the production of extracellular-matrix proteins and either to increase or to decrease the adhesive properties of cells in a cell-specific manner. In many cancer cells the production of TGF-beta is increased, which increases the invasiveness of the cells by increasing their proteolytic activity and promoting their binding to cell-adhesion molecules (see Blobe G C et al., May 2000, “Role of transforming growth factor beta in human disease”, N. Engl. J. Med. 342 (18), 1350-1358).

Thus, therapeutic agents which are able to influence TGF-beta expression and activity, respectively, are essential in particular for use in preventing and/or treating TGF-beta linked diseases. EP 1008649 and EP 0695354, for example, disclose oligonucleotides hybridizing with the mRNA of TGF-beta1 and/or TGF-beta2, and which are suitable to be used for manufacturing pharmaceutical compositions for example for preventing and/or treating cancer. None of these oligonucleotides comprises modifications such as LNA, ENA etc.

WO 2003/85110, WO 2005/061710, and WO 2008/138904 for example refer to oligonucleotides comprising modifications of the nucleotides, which are directed to the inhibition of HIF-1A, Bcl-2 and HER3, respectively, usable in the treatment of cancer.

Criteria for the selection of oligonucleotides are mainly the length of the oligonucleotide, the GC-percentage, the tendency for hairpin formation, dimerization and the melting temperature (Tm). In general, high Tm (melting temperature) is preferred. Furthermore, the oligonucleotides must be specific for the target mRNA and shall not hybridize to non-target mRNAs in order to decrease potential off-target effects.

Hence, there is a high scientific and medical need for therapeutic agents, which reduce or inhibit TGF-beta expression and/or activity. Particularly, there is a long-standing need for oligonucleotides such as antisense oligonucleotides, which specifically interact and thus, reduce or inhibit the expression of TGF-beta1, TGF-beta2, and/or TGF-beta3, as well as oligonucleotides, which specifically inhibit TGF-beta1 and TGF-beta2, or TGF-beta1 and TGF-beta3, or TGF-beta2 and TGF-beta3, without causing any (severe) side effects.

SUMMARY OF THE INVENTION

The present invention refers to oligonucleotides consisting of 10 to 20, preferably 12 to 18 nucleotides of the TGF-beta2 nucleic acid sequence of SEQ ID NO. 1 (see FIG. 2a and FIG. 2b ), or of the TGF-beta1 nucleic acid sequence of SEQ ID NO. 335 (see FIG. 12), or of the TGF-beta3 nucleic acid sequence of SEQ ID NO. 336 (see FIG. 25), wherein one or more nucleotide(s) of the oligonucleotide is/are modified. Some of the oligonucleotides of the present invention correspond to TGF-beta1, TGF-beta2, and TGF-beta3, or to TGF-beta1 and TGF-beta2, or TGF-beta1 and TGF-beta3, or TGF-beta2 and TGF-beta3. Preferred oligonucleotides comprise or consist of one of SEQ ID NO. 2 to 149 (TGF-beta2), of one of SEQ ID No. 150-334 (TGF-beta1), or of one of SEQ ID No. 337-402 (TGF-beta3), which are presented in Table 1.

In particular, oligonucleotides of the present invention comprise or consist of 10 to 20, more preferred of 12 to 18 nucleotides of the region of nucleic acid no. 1380 to 1510 of SEQ ID NO. 1, wherein one or more nucleotide(s) of the oligonucleotide is/are modified. These oligonucleotides are highly effective in the reduction and inhibition of TGF-beta2 expression and activity, respectively. A preferred oligonucleotide comprises or consists of SEQ ID NO. 2 (e.g., ASPH36: GACCAGATGCAGGA), SEQ ID NO. 3 (e.g., ASPH80: GCGACCGTGACCAGAT), SEQ ID NO. 4 (e.g., ASPH98: GCGCGACCGTGACC), SEQ ID NO. 5 (e.g., ASPH111: AGCGCGACCGTGA), or SEQ ID NO. 6 (e.g., ASPH121 or ASPH153: GACCGTGACCAGAT), SEQ ID NO. 7 (e.g., ASPH15: CTGCCCGCGGAT), SEQ ID NO. 8 (e.g., ASPH17: TCTGCCCGCGGAT), SEQ ID NO. 9 (e.g., ASPH26 or ASPH27: GGATCTGCCCGCGGA), SEQ ID NO. 10 (e.g., ASPH37: CTTGCTCAGGATCTGCC), SEQ ID NO. 11 (e.g., ASPH52 or 53: GCTCAGGATCTGCCCGCGGA), SEQ ID NO. 12 (e.g., ASPH112: GGATCGCCTCGAT), SEQ ID NO. 13 (e.g., ASPH119: CCGCGGATCGCC), or SEQ ID NO. 31 (e.g., ASPH30: CGATCCTCTTGCGCAT).

In another embodiment the invention refers to an oligonucleotide, comprising or consisting of 10 to 20, more preferred of 12 to 18 nucleotides of the region of nucleic acid no. 2740 to 2810 of the TGF-beta2 nucleic acid sequence of SEQ ID NO. 1, wherein one or more nucleotide(s) of the oligonucleotide is/are modified. These oligonucleotides are highly effective in the reduction and inhibition of TGF-beta2 expression and activity, respectively. A preferred oligonucleotide comprises or consists of SEQ ID NO. 57 (e.g., ASPH65: TCTGAACTAGTACCGCC), SEQ ID NO. 73 (e.g., ASPH82: AACTAGTACCGCCTTT), or SEQ ID NO. 103 (e.g., ASPH115: CTAGTACCGCCTT).

In a further embodiment the invention refers to an oligonucleotide, comprising or consisting of 10 to 20, more preferred of 12 to 18 nucleotides of the region of nucleic acid no. 1660 to 1680 of the TGF-beta2 nucleic acid sequence of SEQ ID NO. 1 wherein one or more nucleotide(s) of the oligonucleotide is/are modified. These oligonucleotides are highly effective in the reduction and inhibition of TGF-beta1 and/or TGF-beta2 expression and activity, respectively. A preferred oligonucleotide comprises or consists of SEQ ID NO. 14 (e.g., ASHP01 or ASPH02: ACCTCCTTGGCGTAGTA), SEQ ID NO. 15 (e.g., ASPH03 or ASPH04: CCTCCTTGGCGTAGTA), SEQ ID NO. 16 (e.g., ASPH05, ASPH06, or ASPH07: CTCCTTGGCGTAGTA), or SEQ ID NO.17 (e.g., ASPH08: TCCTTGGCGTAGTA).

In another embodiment the invention relates to an oligonucleotide, comprising or consisting of 10 to 20, more preferred of 12 to 18 nucleotides, most preferably 13 nucleotides of the region of nucleic acid no. 2390 to 2410 of the TGF-beta2 nucleic acid sequence of SEQ ID NO. 1 wherein one or more nucleotide(s) of the oligonucleotide is/are modified. These oligonucleotides are highly effective in the reduction and inhibition of TGF-beta1, TGF-beta2, and/or TGF-beta3 expression and activity, respectively. A preferred oligonucleotide comprises or consists of SEQ ID NO. 18 (e.g., ASPH9 or ASPH10: CAGAAGTTGGCAT).

In another embodiment the invention relates to an oligonucleotide, comprising or consisting of 10 to 20, more preferred of 12 to 18 nucleotides of the TGF-beta2 nucleic acid sequence of SEQ ID NO. 1 wherein one or more nucleotide(s) of the oligonucleotide is/are modified. These oligonucleotides are highly effective in the reduction and inhibition of TGF-beta1, TGF-beta2, and/or TGF-beta3, most preferably of TGF-beta2 expression and activity, respectively. A preferred oligonucleotide comprises or consists of one of SEQ ID NO. 19 to 56, 58 to 72, 74 to 102, 104 to 138 (e.g., ASHP11-ASPH14, ASPH16, ASPH18-ASPH25, ASPH28-ASPH35, ASPH38-ASPH51, ASPH60-64, ASPH66-ASPH79, ASPH81, ASPH83-ASPH97, ASPH99-ASPH110, ASPH113, ASPH114, ASPH116-118, ASPH120, ASPH122-ASPH152, ASPH154-ASPH183, or T-LNA (SEQ ID NO: 144)).

Preferred oligonucleotides of the present invention are ASPH01, ASPH03, ASPH05, ASPH17, ASPH22, ASPH26, ASPH27, ASPH35, ASPH36, ASPH37, ASPH45, ASPH47, ASPH48, ASPH65, ASPH69, ASPH71, ASPH80, ASPH82, ASPH98, ASPH105, ASPH115, ASPH190, ASPH191, ASPH192, and ASPH193, respectively.

Further preferred oligonucleotides of the present invention are ASPH1000 to ASPH1132 as shown in Table 1, which preferably inhibit the expression and/or activity of TGFbeta1 mRNA. Preferred oligonucleotides this group are for example ASPH1047, ASPH1051, ASPH1059, ASPH1106, ASPH1139, ASPH1150, ASPH1162, ASPH1163, ASPH1175, ASPH1178, and ASPH1181, respectively.

In an alternative embodiment oligonucleotides are preferably inhibiting the expression and/or activity of TGF-beta3 mRNA. Such oligonucleotides are for example ASPH2000, ASPH2001, ASPH2002, ASPH2003, ASPH2004, ASPH2005, ASPH2006, ASPH2007, ASPH2008, ASPH2009, ASPH2010, ASPH2011, ASPH2012, ASPH2013, ASPH2014, ASPH2015, ASPH2016, ASPH2017, ASPH2018, ASPH2019, ASPH2020, ASPH2021, ASPH2022, ASPH2023, ASPH2024, ASPH2025, ASPH2026, ASPH2027, ASPH2028, ASPH2029, ASPH2030, ASPH2031, ASPH2032, ASPH2033, ASPH2034, ASPH2035, ASPH2036, ASPH2037, ASPH2038, ASPH2039, ASPH2040, ASPH2041, ASPH2042, ASPH2043, ASPH2044, ASPH2045, ASPH2046, ASPH2047, ASPH2048, ASPH2049, ASPH2050, ASPH2051, ASPH2052, ASPH2053, ASPH2054, ASPH2055, ASPH2056, ASPH2057, ASPH2058, ASPH2059, ASPH2060, ASPH2061, ASPH2062, ASPH2063, ASPH2064, ASPH2065, and ASPH2066, respectively.

Oligonucleotides of the present invention show an unexpected strong and specific inhibition of TGF-beta1, TGF-beta2, or TGF-beta3, or TGF-beta1 and TGF-beta2. Alternatively, oligonucleotides of the present invention show strong and specific inhibition of TGF-beta1 and TGF-beta3, or TGF-beta1 and TGF-beta2, or TGF-beta2 and TGF-beta3, and in a further alternative TGF-beta1, TGF-beta2 and TGF-beta3.

Modifications of one or more nucleotides of the oligonucleotides of the present invention are selected from the group consisting of LNA, ENA, polyalkylene oxide such as triethylene glycol (TEG), 2′-fluoro, 2′-O-methoxy and 2′-O-methyl. The modifications are preferably located at the 5′- and/or 3′-end of the oligonucleotide. An oligonucleotide comprising such modified nucleotide is a modified oligonucleotide.

Modified nucleotides are for example arranged in a row, one directly next to the other, or in different patterns, where one or more unmodified nucleotides follow a modified nucleotide. For example an oligonucleotide starts with one or more modified nucleotides followed by one or more, e.g., one, two, three or four, unmodified or unlocked nucleotides followed again by one or more modified nucleotides. In one embodiment both ends of the oligonucleotide comprise an identical pattern of modified and unmodified or unlocked nucleotides. In another embodiment, the pattern of modifications at the 3′- and 5′-end differ including that one end does not comprise a modified nucleotide. Preferably the modified oligonucleotides comprise a series of 8 or 9 unlocked nucleotides.

Alternatively, a nucleotide at any other position in the oligonucleotide is modified, or at least one nucleotide at the 5′- and/or 3′-end of the oligonucleotide and at any other position in the oligonucleotide. For example ASPH1071, ASPH1100, ASPH1109, ASPH 1110, ASPH1111, ASPH1115, ASPH1126, ASPH1127 and ASPH1128 belong to a group of TGF-beta oligonucleotides, for example TGF-beta1 oligonucleotides, which comprises modified nucleosides such as LNA, ENA etc. in different patterns, e.g., separated from each other by an unlocked nucleotide. The oligonucleotides comprise either one type of modification, or one or more different modifications. Optionally, at least one phosphate linkage between two consecutive nucleotides (modified or unmodified) of the oligonucleotide is a phosphorothioate or a methylphosphonate. In a preferred embodiment, the oligonucleotides of the present invention are phosphorothioates.

Moreover, the present invention refers to TGF-beta antisense oligonucleotides, which interact and inhibit the expression of more than one TGF-beta isoform, even if the oligonucleotide is not 100% complementary to the TGF-beta1, TGF-beta2 and/or TGF-beta3 sequence. Such antisense oligonucleotides are for example ASPH1024, ASPH1096, ASPH1131 and ASPH1132, respectively. These oligonucleotides preferably interact with TGF-beta sequences of different species such as human and mouse as for example ASPH1131 and ASPH1132, respectively.

All the oligonucleotides of the different embodiments are for use in a method of the prevention and/or treatment of a malignant or a benign tumor, an immunologic disease, fibrosis (e.g., idiopathic pulmonary fibrosis, renal fibrosis, kidney fibrosis), cirrhosis (e.g., liver cirrhosis), scleroderma or related dermatologic diseases, an eye disease such as glaucoma or posterior capsular opacification (PCO), a CNS disease, hair loss etc.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 presents examples of nucleotide modifications.

FIG. 2a and FIG. 2b show the nucleic acid sequence of human TGF-beta2 mRNA (NM_003238.3).

FIG. 3a (i), FIG. 3a (ii), FIG. 3a (iii), FIG. 3b (i), FIG. 3b (ii), FIG. 3b (iii), FIG. 3c )i, FIG. 3c (ii), and FIG. c(iii) depict the inhibition of the expression of TGF-beta1 and TGF-beta2 mRNA in human A172 glioma cells. A172 cells were transfected with different modified oligonucleotides in a dose of 10 nM (in the presence of a transfecting agent), and the inhibition of the TGF-beta1 (white columns) and TGF-beta2 (black columns) mRNA expression was measured 24 h after transfection. FIG. 3a (i), FIG. 3a (ii), FIG. 3a (iii)) refers to the results for the modified oligonucleotides ASPH01, ASPH02, ASPH03, ASPH04, ASPH05, ASPH06, ASPH07, ASPH08, ASPH09, ASPH10, ASPH11, ASPH12, ASPH13, ASPH14, ASPH15, ASPH16, ASPH17, ASPH18, ASPH19, ASPH20, ASPH21, ASPH22, ASPH24, ASPH25, ASPH26, ASPH27, ASPH29, ASPH30, ASPH31, ASPH32, ASPH33, ASPH34, ASPH35, ASPH36, ASPH37, ASPH38, ASPH39, ASPH40, ASPH41, ASPH42, ASPH43, ASPH44, ASPH45, ASPH46, ASPH47, ASPH48, ASPH49, ASPH50, ASPH51, ASPH52, ASPH53, and ASPH54; FIG. 3b (i), FIG. 3b (ii), FIG. 3b (iii)) to the results for the modified oligonucleotides ASPH36, ASPH60, ASPH61, ASPH62, ASPH63, ASPH64, ASPH65, ASPH66, ASPH67, ASPH68, ASPH69, ASPH70, ASPH71, ASPH72, ASPH73, ASPH74, ASPH75, ASPH76, ASPH77, ASPH78, ASPH79, ASPH80, ASPH81, ASPH82, ASPH83, ASPH84, ASPH85, ASPH86, ASPH87, ASPH88, ASPH89, ASPH90, ASPH91, ASPH92, ASPH93, ASPH94, ASPH95, ASPH96, ASPH97, ASPH98, ASPH99, ASPH100, ASPH101, ASPH102, ASPH103, ASPH104, ASPH105, ASPH106, ASPH107, ASPH108, ASPH109, ASPH110, ASPH111, ASPH112, ASPH113, ASPH114, ASPH115, ASPH116, ASPH117, ASPH118, and ASPH119; and FIG. 3c (i), FIG. 3c (ii), FIG. 3c (iii)) to the results for the modified oligonucleotides ASPH36, ASPH71, ASPH73, ASPH120, ASPH121, ASPH122, ASPH123, ASPH124, ASPH125, ASPH126, ASPH127, ASPH128, ASPH129, ASPH130, ASPH131, ASPH132, ASPH133, ASPH134, ASPH135, ASPH136, ASPH137, ASPH138, ASPH139, ASPH140, ASPH141, ASPH142, ASPH143, ASPH145, ASPH146, ASPH147, ASPH148, ASPH149, ASPH150, ASPH151, ASPH152, ASPH153, ASPH154, ASPH155, ASPH157, ASPH158, ASPH160, ASPH161, ASPH162, ASPH163, ASPH164, ASPH165, ASPH166, ASPH167, ASPH168, ASPH169, ASPH170, ASPH171, ASPH172, ASPH173, ASPH174, ASPH175, ASPH176, ASPH177, ASPH178, ASPH179, ASPH180, ASPH181, ASPH182, and ASPH183. Experiments are described in Example 1.

FIG. 4a (i), FIG. 4a (ii), FIG. 4b (i), FIG. 4b (ii), FIG. 4b (iii), and FIG. 4c (i), FIG. 4c (ii), and FIG. 4c (iii) depict the inhibition of the expression of TGF-beta1 and TGF-beta2 mRNA in human Panc-1 pancreatic cancer cells. Panc-1 cells were transfected with different modified oligonucleotides in a dose of 10 nM (in the presence of a transfecting agent), and the inhibition of the TGF-beta1 (white columns) and TGF-beta2 (black columns) mRNA expression was measured 24 h after transfection. FIG. 4a (i), and FIG. 4a (ii), refer to the results for the modified oligonucleotides ASPH01, ASPH02, ASPH03, ASPH04, ASPH05, ASPH06, ASPH07, ASPH08, ASPH12, ASPH14, ASPH17, ASPH18, ASPH20, ASPH21, ASPH22, ASPH24, ASPH25, ASPH26, ASPH27, ASPH29, ASPH30, ASPH31, ASPH32, ASPH33, ASPH35, ASPH36, ASPH37, ASPH38, ASPH39, ASPH40, ASPH41, ASPH42, ASPH43, ASPH44, ASPH45, ASPH46, ASPH47, ASPH48, ASPH49, ASPH50, ASPH51, and ASPH52; FIG. 4b (i), FIG. 4b (ii), and FIG. 4b (iii)) to the results for the modified oligonucleotides ASPH36, ASPH60, ASPH61, ASPH62, ASPH63, ASPH64, ASPH65, ASPH66, ASPH67, ASPH68, ASPH69, ASPH70, ASPH71, ASPH72, ASPH73, ASPH74, ASPH75, ASPH76, ASPH77, ASPH78, ASPH79, ASPH80, ASPH81, ASPH82, ASPH83, ASPH84, ASPH85, ASPH86, ASPH87, ASPH88, ASPH89, ASPH90, ASPH91, ASPH92, ASPH93, ASPH94, ASPH96, ASPH97, ASPH98, ASPH99, ASPH100, ASPH101, ASPH102, ASPH103, ASPH104, ASPH105, ASPH106, ASPH107, ASPH108, ASPH109, ASPH110, ASPH111, ASPH112, ASPH113, ASPH114, ASPH115, ASPH116, ASPH117, ASPH118, and ASPH119; and FIG. 4c (i), FIG. 4c (ii), and FIG. 4c (iii)) to the results for the modified oligonucleotides ASPH36, ASPH71, ASPH73, ASPH120, ASPH121, ASPH122, ASPH127, ASPH128, ASPH129, ASPH130, ASPH131, ASPH132, ASPH133, ASPH135, ASPH136, ASPH137, ASPH139, ASPH141, ASPH142, ASPH143, ASPH145, ASPH146, ASPH147, ASPH149, ASPH150, ASPH151, ASPH152, ASPH153, ASPH154, ASPH155, ASPH157, ASPH160, ASPH161, ASPH162, ASPH163, ASPH164, ASPH165, ASPH166, ASPH167, ASPH168, ASPH169, ASPH170, ASPH171, ASPH172, ASPH173, ASPH174, ASPH175, ASPH176, ASPH177, ASPH178, ASPH179, ASPH180, ASPH181, ASPH182, and ASPH183. Experiments are described in Example 2.

FIG. 5a and FIG. 5b show the inhibition of the expression of TGF-beta1 and TGF-beta2 mRNA in Panc-1 cells. Panc-1 cells were treated with different modified oligonucleotides in a dose of 3.3 μM in the absence of any transfection reagent (gymnotic transfection or unassisted transfection or gymnotic delivery), and the inhibition of the TGF-beta1 (white columns) and TGF-beta2 (black columns) mRNA expression was measured after 72 h. FIG. 5a and FIG. 5b present the results for the modified oligonucleotides ASPH17, ASPH18, ASPH22, ASPH25, ASPH33, ASPH35, ASPH36, ASPH41, ASPH42, ASPH45, ASPH46, ASPH47, ASPH48, ASPH49, ASPH65, ASPH66, ASPH67, ASPH69, ASPH71, ASPH79, ASPH80, ASPH82, ASPH88, ASPH89, ASPH90, ASPH91, ASPH98, ASPH99, ASPH102, ASPH105, ASPH111, ASPH115, ASPH119, ASPH121, ASPH139, ASPH140, ASPH146, ASPH151, ASPH153, ASPH165, ASPH171, ASPH172, ASPH176, ASPH178, ASPH180, and ASPH183. Experiments are described in Example 4.

FIG. 6a presents the inhibition of the expression of TGF-beta1 mRNA and FIG. 6b presents the inhibition of the expression of TGF-beta2 mRNA. FIG. 7a presents the inhibition of TGF-beta1 protein in Panc-1 cells and FIG. 7b presents the inhibition of TGF-beta2 protein in Panc-1 cells. Panc-1 cells were treated with different modified oligonucleotides in a dose of 10 μM via gymnotic delivery, i.e., in the absence of any transfecting reagent, and the inhibition of the TGF-beta1 and TGF-beta2 mRNA expression and protein was measured 4 days after transfection. FIG. 6a ) and FIG. 6b ) show the results for the modified oligonucleotides ASPH01, ASPH03, ASPH05, ASPH09, ASPH17, ASPH18, ASPH22, ASPH35, ASPH36, ASPH37, ASPH41, ASPH45, ASPH46, ASPH47, and ASPH48 on mRNA (FIG. 7a ) and protein (FIG. 7b ) level. Experiments are described in Example 5.

FIG. 8a and FIG. 8b depicts the dose-dependent effect of modified oligonucleotides ASPH05 and ASPH36 on TGF-beta1 and TGF-beta2 mRNA expression. Panc-1 cells were treated for 4 days with 15 μM, 10 μM, 7.5 μM, 5 μM, 2.5 μM, 1.25 μM, or 0.625 μM of either ASPH05 (dual TGF-beta1 and TGF-beta2 oligonucleotide) or ASPH36 (selective TGF-beta2 oligonucleotide) modified oligonucleotide in the absence of a transfection reagent. Remaining TGF-beta1 (FIG. 8a ) or TGF-beta2 mRNA (FIG. 8b ) was measured after 4 days. Experiments are described in Example 6.

FIG. 9 shows the inhibition of the expression of TGF-beta1 and TGF-beta2 mRNA in mouse SMA-560 glioma cells. SMA-560 cells were transfected with ASPH01, ASPH03, ASPH05, ASPH09, ASPH17, ASPH18, ASPH22, ASPH26, ASPH36, ASPH37, ASPH41, ASPH42, ASPH45, ASPH46, ASPH47, or ASPH48 in a dose of 10 nM (in the presence of a transfecting agent). Inhibition of the mouse TGF-beta1 (white columns) and TGF-beta2 (black columns) mRNA expression was determined 24 h after transfection. Experiments are described in Example 7.

FIG. 10 presents in vivo data referring to the treatment of female athymic nude mice with ASPH01, ASPH03, ASPH05, ASPH17, ASPH22, ASPH37, ASPH41, ASPH45, ASPH46, ASPH47, or ASPH48 at 14 mg/kg body weight by subcutaneous injection for 5 consecutive days. 24 h after the last treatment, mice were sacrificed and mouse TGF-beta 2 mRNA was quantified in kidney tissue lysates. Data—representing TGF-beta2 to GAPDH mRNA ratio—are shown as a box plot in which median values and min. and max. values are presented (data expressed as n=4, except ASPH46 group n=3). Experiments are described in Example 8.

FIG. 11 shows the inhibition of the expression of TGF-beta3 mRNA in Panc-1 cells. Panc-1 cells were treated with ASPH09 in a dose of 10 μM in the absence of any transfection reagent (gymnotic transfection or unassisted transfection), and inhibition of the TGF-beta3 mRNA expression was measured after 4 days. ASPH09 is a pan-specific oligonucleotide inhibiting the expression of TGF-beta3 as well as TGF-beta1 and TGF-beta2 (FIG. 6a and FIG. 6b ). Experiment is described in Example 9.

FIG. 12 presents the nucleic acid sequence of human TGF-beta1 mRNA (NM_000660.4).

FIG. 13a and FIG. 13b depicts the inhibition of the expression of TGF-beta1 mRNA in human Panc-1 pancreatic cancer cells. Panc-1 cells were transfected with different modified oligonucleotides in a dose of 10 nM (in the presence of a transfecting agent), and inhibition of the TGF-beta1 mRNA expression was measured 24 h after transfection. FIG. 13a and FIG. 13b refer to the results for the modified oligonucleotides ASPH05, ASPH09, ASPH1000, ASPH1001, ASPH1002, ASPH1003, ASPH1004, ASPH1005, ASPH1006, ASPH 1007, ASPH1008, ASPH1009, ASPH1010, ASPH1011, ASPH1012, ASPH1013, ASPH1014, ASPH1015, ASPH1016, ASPH1017, ASPH1018, ASPH1019, ASPH1020, ASPH1021, ASPH1022, ASPH1023, ASPH1024, ASPH1026, ASPH1027, ASPH1028, ASPH1029, ASPH1030, ASPH1031, ASPH1032, ASPH1033, ASPH1034, ASPH1035, ASPH1036, ASPH 1038, ASPH1039, ASPH1040, ASPH1041, ASPH1042, ASPH1043, ASPH1044, ASPH1045, ASPH1046, ASPH1047, ASPH1048, ASPH1049, ASPH1050, ASPH1051, ASPH1052, ASPH1054, ASPH1055, ASPH1056, ASPH1057, ASPH1058, ASPH1059, ASPH1060, and ASPH1061. Experiments are described in Example 12.

FIG. 14 shows the inhibition of the expression of TGF-beta1 mRNA in mouse SMA-560 glioma cells. Cells were transfected with different modified oligonucleotides in a dose of 10 nM (in the presence of a transfecting agent), and inhibition of the TGF-beta1 mRNA expression was measured 24 h after transfection. FIG. 14 refers to the results for the modified oligonucleotides ASPH09, ASPH1000, ASPH1001, ASPH1002, ASPH1003, ASPH1004, ASPH1005, ASPH1006, ASPH1007, ASPH1008, ASPH1009, ASPH1010, ASPH1011, ASPH1012, ASPH1013, ASPH1014, ASPH1015, ASPH1016, ASPH1017, ASPH1018, ASPH1019, ASPH 1020, ASPH1021, ASPH1022, ASPH1023, ASPH1024, ASPH1026, ASPH1027, ASPH1028, ASPH1029, ASPH1030, ASPH1031, ASPH1032, ASPH1033, ASPH1034, ASPH1035, ASPH1036, ASPH1037, ASPH1038, ASPH1039, ASPH1040, ASPH1041, ASPH1042, ASPH1043, ASPH1044, ASPH1045, ASPH1046, ASPH1047, ASPH1048, ASPH1049, ASPH1050, ASPH1051, ASPH1052, ASPH1053, ASPH1054, ASPH1055, ASPH1056, ASPH1057, ASPH1058, ASPH1059, ASPH1060, ASPH1061, and ASPH1062. Experiments are described in Example 13.

FIG. 15a , FIG. 15b , and FIG. 15c depict the inhibition of the expression of TGF-beta1 and TGF-beta2 mRNA in human A172 cells. Cells were transfected with different modified oligonucleotides in a dose of 10 nM (in the presence of a transfecting agent), and inhibition of the TGF-beta1 and TGF-beta2 mRNA expression was measured 24 h after transfection. FIG. 15a , FIG. 15b , and FIG. 15c refer to the results for the modified oligonucleotides ASPH05, ASPH09, ASPH1000, ASPH1001, ASPH1002, ASPH1004, ASPH1005, ASPH1006, ASPH1007, ASPH1008, ASPH1009, ASPH1010, ASPH1011, ASPH1012, ASPH1013, ASPH1014, ASPH1015, ASPH1016, ASPH1017, ASPH1018, ASPH1019, ASPH1020, ASPH1021, ASPH1022, ASPH1023, ASPH1024, ASPH1026, ASPH1027, ASPH1028, ASPH1029, ASPH1030, ASPH1031, ASPH1032, ASPH1033, ASPH1034, ASPH1035, ASPH1036, ASPH1038, ASPH1039, ASPH1040, ASPH1041, ASPH1042, ASPH1043, ASPH1044, ASPH1045, ASPH1046, ASPH1047, ASPH1048, ASPH1049, ASPH1050, ASPH1051, ASPH1052, ASPH1053, ASPH1054, ASPH1056, ASPH1057, ASPH1058, ASPH1059, ASPH1060, ASPH1061, and ASPH1062. Experiments are described in Example 14.

FIG. 16a , FIG. 16b , and FIG. 16c show the inhibition of the expression of TGF-beta1 and TGF-beta2 mRNA in Panc-1 cells. Panc-1 cells were treated with different modified oligonucleotides in a dose of 3.3 μM in the absence of any transfection reagent (gymnotic transfection or unassisted transfection or gymnotic delivery), and inhibition of the TGF-beta1 (black columns) and TGF-beta2 (white columns) mRNA expression was measured after 72 h.

FIG. 16a , FIG. 16b , and FIG. 16c refer to the results for the modified oligonucleotides ASPH05, ASPH09, ASPH1000, ASPH1001, ASPH1002, ASPH1004, ASPH1006, ASPH1007, ASPH1008, ASPH1009, ASPH1010, ASPH1011, ASPH1012, ASPH1013, ASPH1014, ASPH1015, ASPH1017, ASPH1018, ASPH1019, ASPH1020, ASPH1021, ASPH1022, ASPH1024, ASPH1026, ASPH1027, ASPH1028, ASPH1029, ASPH1032, ASPH1033, ASPH1034, ASPH1035, ASPH1036, ASPH1037, ASPH1038, ASPH1039, ASPH1040, ASPH1041, ASPH1042, ASPH1043, ASPH1044, ASPH1045, ASPH1046, ASPH1047, ASPH1049, ASPH1050, ASPH1051, ASPH1052, ASPH1053, ASPH1054, ASPH1055, ASPH1056, ASPH1057, ASPH1058, ASPH1059, ASPH1060, ASPH1061, and ASPH1062. Experiments are described in Example 15.

FIG. 17 depicts the inhibition of the expression of TGF-beta1, TGF-beta2 and TGF-beta3 mRNA in human A172 cells. Cells were transfected with different modified oligonucleotides in a dose of 10 nM (in the presence of a transfecting agent), and inhibition of the TGF-beta1 (black column), TGF-beta2 (white column) and TGF-beta3 (striped column) mRNA expression was measured 24 h after transfection. FIG. 17 refers to the results for the modified oligonucleotides ASPH09, ASPH1047, ASPH1051, ASPH1059, ASPH1063, ASPH1064, ASPH1065, ASPH1066, ASPH1067, ASPH1068, ASPH1069, ASPH1070, ASPH1071, ASPH1072, ASPH1073, ASPH1074, ASPH1075, ASPH1076, ASPH1077, ASPH1078, ASPH1079, ASPH1080, ASPH1081, ASPH1082, ASPH1083, ASPH1084, ASPH1085, ASPH1086, ASPH1087, ASPH1088, ASPH1089, ASPH1090, ASPH1091, ASPH1092, ASPH1093, ASPH1094, ASPH1095, ASPH1097, ASPH1098, ASPH1099, ASPH1100, ASPH1101, ASPH1102, ASPH1103, ASPH1104, ASPH1105, ASPH1106, ASPH1107, ASPH1108, ASPH1109, ASPH1110, ASPH1111, ASPH1112, ASPH1113, ASPH114, ASPH1115, ASPH1116, ASPH1117, ASPH1118, ASPH1119, ASPH1120, ASPH1121, ASPH1122, ASPH1123, ASPH1124, ASPH1125, ASPH1126, ASPH1127, ASPH1128, ASPH1129, ASPH1130, ASPH1131, and ASPH1132. Experiments are described in Example 16.

FIG. 18a (i), and FIG. 18a (ii) show the inhibition of the expression of TGF-beta1, TGF-beta2 and TGF-beta3 mRNA in human Panc-1 and RenCa cells. Cells were transfected with different modified oligonucleotides in a dose dose of 3.3 μM in the absence of any transfection reagent (gymnotic transfection or unassisted transfection or gymnotic delivery), and inhibition of the TGF-beta1 (black column), TGF-beta2 (white column) and TGF-beta3 (striped column) mRNA expression was measured 72 h after transfection. FIG. 18a (i), and FIG. 18a (ii) refer to the results for the modified oligonucleotides ASPH1063, ASPH1064, ASPH1065, ASPH1066, ASPH1067, ASPH1068, ASPH1069, ASPH1070, ASPH1071, ASPH1072, ASPH1073, ASPH1074, ASPH1075, ASPH1076, ASPH1077, ASPH1078, ASPH1079, ASPH1080, ASPH1081, ASPH1082, ASPH1083, ASPH1084, ASPH1085, ASPH1086, ASPH1087, ASPH1088, ASPH1089, ASPH1090, ASPH1091, ASPH1092, ASPH1093, ASPH1094, ASPH1095, ASPH1097, ASPH1098, ASPH1099, ASPH1100, ASPH1101, ASPH1102, ASPH1103, ASPH1104, ASPH1105, ASPH1106, ASPH1107, ASPH1108, ASPH1109, ASPH1110, ASPH1111, ASPH1112, ASPH1113, ASPH114, ASPH1115, ASPH1116, ASPH1117, ASPH1118, ASPH1119, ASPH1120, ASPH1121, ASPH1122, ASPH1123, ASPH1124, ASPH1125, ASPH1126, ASPH1127, ASPH1128, ASPH1129, ASPH1130, ASPH1131, and ASPH1132. FIG. 18b presents the inhibiting effect of these oligonucleotides in RenCa cells.

FIG. 19 presents a sequence alignment of ASPH1024 and ASPH1096 with the human sequence of TGF-beta1, TGF-beta2 and TGF-beta3 mRNAs. Both oligonucleotides are 100% homologous to the human sequence of TGF-beta1. ASPH1024 has three mismatches with the human sequence of TGF-beta2 and two mismatches with human sequence of TGF-beta3. ASPH1096 has one mismatch with the human sequence of TGF-beta2, and one mismatch with the human sequence of TGF-beta3. Both oligonucleotides show inhibition of different human TGF-beta isoforms (TGF-beta1, TGF-beta2, and TGF-beta3). For example ASPH1024 inhibits the expression and activity of TGF-beta1 and TGF-beta2 (see FIG. 16a , FIG. 16b , and FIG. 16c ) and ASPH1096 inhibits the expression and activity of TGF-beta1, TGF-beta2 and TGF-beta3 as depicted in FIG. 17 for example. ASPH009, which is 100% homologous to the human sequence of TGF-beta1, TGF-beta2, and TGF-beta3 was used as a control.

FIG. 20 shows an alignment of ASPH1131 and ASPH1132 with the human sequences of TGF-beta1, TGF-beta2 and TGF-beta3 mRNAs. Both oligonucleotides are 100% homologous to the human sequences of TGF-beta1 and TGF-beta3. Each of ASPH1131 and ASPH1132 has one mismatch with the human sequence of TGF-beta2. Both oligonucleotides strongly inhibit the expression of all three human isoforms as depicted in FIG. 17 for example.

FIG. 21 depicts an alignment of ASPH1131 and ASPH1132 with the murine sequences of TGF-beta1, TGF-beta2 and TGF-beta3 mRNAs. Both oligonucleotides are 100% homologous to the murine sequences of TGF-beta1 and TGF-beta3. Each of ASPH1131 and ASPH1132 has two mismatches with the murine sequence of TGF-beta2. While ASPH1131 potently inhibits murine TGF-beta2 and TGF-beta3, ASPH1132 very potently suppresses all murine TGF-beta isoforms as depicted in FIG. 18b for example.

FIG. 22 shows TGF-beta2 mRNA expression in the kidney of mice bearing subcutaneous human pancreatic carcinoma Panc-1. Mice were treated with 1, 3, 10, and 30 mg/kg of ASPH47 after indicated treatment schedules for 5 days: Q1Dx1-d6 (single SC injection, termination 5 days later), Q1Dx5-d6 (daily SC injection for 5 days, termination 24 hours later), and Q1Dx5-d10 (daily SC injection for 5 days, termination 5 days later). TGF-beta2 expression was detected by bDNA assay and normalized to GAPDH. Data—representing TGF-beta2 to GAPDH mRNA ratio—are shown as a box plot in which median values and min. and max. values are presented (data expressed as n=10, except n=9 for vehicle and 3 mg/kg Q1Dx1 d6 groups).

FIG. 23 depicts TGF-beta2 mRNA expression in the kidneys of mice bearing human pancreatic carcinoma Panc-1 tumors. Mice were treated with subcutaneous injections of various oligonucleotides for 5 consecutive days using indicated treatment doses: daily injection of 1, 5, 15 or 50 mg/kg oligonucleotides for five consecutive days. TGF-beta2 mRNA expression was detected by bDNA assay and normalized to GAPDH. Data—representing TGF-beta2 to GAPDH mRNA ratio—are shown as a box plot in which median values and min. and max. values are presented (data expressed as n=5).

FIG. 24 presents TGF-beta2 mRNA expression in subcutaneous human renal cell carcinomas 786-O tumors. Mice were treated with a daily injection of 50 mg/kg oligonucleotides for five consecutive days. TGF-beta2 and GAPDH mRNA expression was detected by bDNA. Data—representing TGF-beta2 to GAPDH mRNA ratio—are shown as a box plot in which median values and min. and max. values are presented (data expressed as n=10, except for ASPH71 group n=9).

FIG. 25 shows the nucleic acid sequence of human TGF-beta3 mRNA (NM_003239.2).

FIG. 26a , FIG. 26b , FIG. 26c , FIG. 26d , FIG. 26e , and FIG. 26f depict the inhibiting effect of oligonucleotides of the present invention on the expression of TGF-beta1 and TGF-beta2 protein. Panc-1 cells were transfected with 20, 6.67, 2.22, 0.74, 0.25, 0.08 or 0.009 μM of the modified oligonucleotides ASPH47 (FIG. 26a ), ASPH1047 (FIG. 26b ), ASPH1106 (FIG. 26c ), ASPH1132 (FIG. 26d ), or ASPH47 in combination with ASPH1047 (FIG. 26e ). Negative control is the scrambled oligonucleotide (scrLNA) of SEQ ID No. 145 (FIG. 26f ) in concentrations of 40, 13.33, 4.44, 1.48, 0.49, 0.16, 0.05, or 0.02 μM. TGF-beta1 (diamonds) and TGF-beta2 protein (squares) levels in cell supernatants were determined by ELISA.

FIG. 27a and FIG. 27b present the inhibiting effect of oligonucleotides of the present invention on the expression of TGF-beta1, TGF-beta2, and TGF-beta3. Panc-1 cells (FIG. 27a ) or RenCa cells (FIG. 27b ) were transfected with 3.3 μM of different TGF-beta specific oligonucleotides in the absence of a transfecting agent. The expression of TGF-beta1 (black column), TGF-beta2 (white column) and TGF-beta3 (striped column) mRNA was determined 72 h after transfection.

FIG. 28 depicts the inhibiting effect of oligonucleotides of the present invention on the expression of TGF-beta1, TGF-beta2, and TGF-beta3. A172 glioma cells were transfected with 10 nM of different TGF-beta specific oligonucleotides in the presence of transfecting agent. The expression of TGF-beta1 (black column), TGF-beta2 (white column) and TGF-beta3 (striped column) mRNA was determined 24 h after transfection.

FIG. 29a and FIG. 29b present a compared analysis of time-dependent plasma (29a) and kidney (29b) concentration (PK profiles; with values expressed in μg/mL or μg/gr) and downregulation of TGF-β2 mRNA (PD profile) in kidney following single subcutaneous bolus administration of 50 mg/kg of ASPH_0047 to Balb/c mice.

FIG. 30 depicts TGF-β2 mRNA downregulation in established subcutaneous tumors (FIG. 30A-D) or kidney (FIG. 30E-F) in immunodeficient mouse following subcutaneous repeated administration of ASPH_0047 or control oligonucleotide. TGF-beta2 and GAPDH mRNA expression was detected by bDNA. Results are expressed as TGF-beta2/GAPDH mRNA ratio, and each individual tested sample is represented with line indicating median values.

FIG. 31 shows the effect of systemic treatment of Balb/c mice with ASPH_0047 (selective TGF-b2 antisense oligonucleotide) on lung metastasis in orthotopic and in i.v. mouse Renca renal carcinoma model. Level of lung metastasis was determined by either number of metastasis or based on lung weight. Results are shown as a box plot in which median values, upper and lower quartiles, and 90^(th) and 10^(th) percentiles are presented.

FIG. 32 presents human Panc-1 pancreatic cancer cells were treated with 3.3 μM of the indicated oligonucleotides in the absence of transfecting agent (gymnotic transfection or gymnotic delivery). The expression of TGF-beta1 (black column), TGF-beta2 (white column) and TGF-beta3 (striped column) mRNA was determined 72 h after transfection.

FIG. 33 depicts the effect of systemic treatment of Balb/c mice with ASPH_0047 on lung metastasis in orthotopic mouse 4T1 mammary carcinoma model. Data for each individual animal is represented with median values indicated as bold black line.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to oligonucleotides, in particular antisense oligonucleotides, which comprise at least one modified nucleotide and are suitable to interact with TGF-beta mRNA. The oligonucleotides comprise or consist of 10 to 20, more preferred 12 to 18 nucleotides of the TGF-beta2 nucleic acid according to SEQ ID NO. 1 or of the TGF-beta1 nucleic acid according to SEQ ID NO. 335, or of the nucleic acid sequence of TGF-beta3 nucleic acid according to SEQ ID NO. 336. Most preferred the oligonucleotide comprises or consists of 12, 13, 14, 15, 16, 17, or 18 nucleotides. The oligonucleotides are preferably selected from the region of nucleic acid no. 1380 to 1510 (preferably no. 1380 to 1450 and/or no. 1480 to 1510), 1660 to 1680, or 2390 to 2410 of SEQ ID NO. 1. The oligonucleotide is a single or double stranded RNA or DNA, including siRNA, microRNA, aptamer or spiegelmer. Preferably, the oligonucleotide is an antisense oligonucleotide.

A nucleotide forms the building block of an oligonucleotide, and is for example composed of a nucleobase (nitrogenous base, e.g., purine or pyrimidine), a five-carbon sugar (e.g., ribose, 2-deoxyribose, arabinose, xylose, lyxose, allose, altorse, glucose, mannose, gulose, idose, galactose, talose or stabilized modifications of those sugars), and one or more phosphate groups. Examples of modified phosphate groups are phosphorothioate or methylphosphonate. Each compound of the nucleotide is modifiable, and is naturally or non-naturally occurring. The latter are for example locked nucleic acid (LNA), a 2′-O,4′-C-ethylene-bridged nucleic acid (ENA), polyalkylene oxide—(such as triethylene glycol (TEG)), 2′-fluoro, 2′-O-methoxy and 2′-O-methyl modified nucleotides as described for example by Freier & Altmann (Nucl. Acid Res., 1997, 25, 4429-4443) and Uhlmann (Curr. Opinion in Drug & Development (2000, 3 (2): 293-213), which are shown in FIG. 1.

A LNA is a modified RNA nucleotide, wherein the ribose moiety is modified with an extra bridge connecting the 2′oxygen and 4′carbon (2′-4′ribonucleoside). The bridge “locks” the ribose in the 3′-endo (North) conformation, which is often found in the A-form duplexes. LNA nucleosides and nucleotides, respectively, comprise for example the forms of thio-LNA, oxy-LNA, or amino-LNA, in alpha-D- or beta-L-configuration, and are mixable and combinable, respectively, with DNA or RNA residues in the oligonucleotide.

The oligonucleotides of the present invention, i.e., modified oligonucleotides, comprise at least one modified nucleotide, preferably LNA and/or ENA, at the 5′- and/or 3′-end of the oligonucleotide. In a preferred embodiment, the oligonucleotide comprises 1, 2, 3, or 4 LNAs or ENAs at the 5′-end, and 1, 2, 3, or 4 LNAs or ENAs at the 3′-end. In another preferred embodiment, the oligonucleotide comprises 1, 2, 3, or 4 LNAs or ENAs at the 5′-end or 3′-end, and a polyalkylene oxide such as TEG at the 3′- or 5′-end. The modified oligonucleotides show a significantly increased inhibition on TGF-beta expression and activity, respectively, which results in an improved prevention and/or treatment of a malignant or benign tumor, fibrosis (e.g., idiopathic pulmonary fibrosis, renal fibrosis, kidney fibrosis), cirrhosis (e.g., liver cirrhosis), scleroderma or related dermatologic diseases, an eye disease such as glaucoma or posterior capsular opacification (PCO), a CNS disease, hair loss etc. The oligonucleotides of the present invention target TGF-beta linked diseases either by hybridization with TGF-beta mRNA, preferably TGF-beta1, TGF-beta2, or TGF-beta3, alternatively, TGF-beta1, TGF-beta2, and/or TGF-beta3 mRNAs, i.e., TGF-beta1 and TGF-beta2, or TGF-beta1 and TGF-beta3, or TGF-beta2 and TGF-beta3, or TGF-beta1, TGF-beta2 and TGF-beta3 mRNAs, or any other direct or indirect effect on the TGF-beta system.

Preferably two or more oligonucelotides are combined, wherein at least one oligonucleotide specifically inhibits TGF-beta1 and at least one oligonucleotide specifically inhibits TGF-beta2, or wherein at least one oligonucleotide specifically inhibits TGF-beta1 and at least one oligonucleotide specifically inhibits TGF-beta3, or wherein at least one oligonucleotide specifically inhibits TGF-beta2 and at least one oligonucleotide specifically inhibits TGF-beta3, or wherein at least one oligonucleotide specifically inhibits TGF-beta1, at least one oligonucleotide specifically inhibits TGF-beta2, and at least one oligonucleotide specifically inhibits TGF-beta3.

In another embodiment, one oligonucleotide inhibits two TGF-beta isoforms such as TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, or TGF-beta1 and TGF-beta3. An oligonucleotide inhibiting the expression of all three isoforms—TGF-beta1, TGF-beta2, and TGF-beta3—is defined as pan-specific oligonucleotide.

In a further embodiment three or more oligonucleotides are combined, wherein at least one oligonucleotide specifically inhibits TGF-beta1, another oligonucleotide specifically inhibits TGF-beta2, and a further oligonucleotide specifically inhibits TGF-beta3, and optionally one or more additional oligonucleotides inhibiting TGF-beta1, TGF-beta2 or TGF-beta3.

The oligonucleotides of the present invention have for example an IC₅₀ in the range of 0.1 to 20 μM, preferably in the range of 0.2 to 15 μM, more preferably in the range of 0.4 to 10 μM, and even more preferred in the range of 0.5 to 5 μM.

The present invention further refers to a pharmaceutical composition comprising an oligonucleotide according to the invention as active ingredient. The pharmaceutical composition comprises at least one oligonucleotide of the present invention and optionally further an antisense compound, an antibody, a chemotherapeutic compound, an anti-inflammatory compound, an antiviral compound and/or an immuno-modulating compound. Pharmaceutically acceptable binding agents and adjuvants or carrier optionally comprise part of the pharmaceutical composition.

In one embodiment, the oligonucleotide and the pharmaceutical composition, respectively, is formulated as dosage unit in form of capsules, tablets and pills etc., respectively, which contain for example the following compounds: microcrystalline cellulose, gum or gelatin as binders; starch or lactose as excipients; stearates as lubricants, various sweetening or flavouring agents. For capsules the dosage unit may contain a liquid carrier like fatty oils. Likewise coatings of sugar or enteric agents may be part of the dosage unit.

The oligonucleotide and/or the pharmaceutical composition is administrable via different routes. These routes of administration include, but are not limited to, electroporation, epidermal, impression into skin, intra-arterial, intra-articular, intracranial, intradermal, intra-lesional, intra-muscular, intranasal, intra-ocular, intrathecal, intracameral, intraperitoneal, intraprostatic, intrapulmonary, intraspinal, intratracheal, intratumoral, intravenous, intravesical, placement within cavities of the body, nasal inhalation, oral, pulmonary inhalation (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer), subcutaneous, subdermal, topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), or transdermal administration.

For parenteral, subcutaneous, intradermal or topical administration the oligonucleotide and/or the pharmaceutical composition include for example a sterile diluent, buffers, regulators of toxicity and antibacterials. In a preferred embodiment, the oligonucleotide or pharmaceutical composition is prepared with carriers that protect against degradation or immediate elimination from the body, including implants or microcapsules with controlled release properties. For intravenous administration the preferred carriers are for example physiological saline or phosphate buffered saline. An oligonucleotide and/or a pharmaceutical composition comprising such oligonucleotide for oral administration includes for example powder or granule, microparticulate, nanoparticulate, suspension or solution in water or non-aqueous media, capsule, gel capsule, sachet, tablet or minitablet. An oligonucleotide and/or a pharmaceutical composition comprising for parenteral, intrathecal, intracameral or intraventricular administration includes for example sterile aqueous solutions which optionally contain buffer, diluent and/or other suitable additive such as penetration enhancer, carrier compound and/or other pharmaceutically acceptable carrier or excipient.

A pharmaceutically acceptable carrier is for example liquid or solid, and is selected with the planned manner of administration in mind so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutically acceptable carriers include, but are not limited to, a binding agent (e.g. pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); filler (e.g. lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricant (e.g., magnesium stearate, talcum, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrate (e.g., starch, sodium starch glycolate, etc.); or wetting agent (e.g., sodium lauryl sulphate, etc.). Sustained release oral delivery systems and/or enteric coatings for orally administered dosage forms are described in U.S. Pat. Nos. 4,704,295; 4,556,552; 4,309,406; and 4,309,404. An adjuvant is included under these phrases.

Beside being used in a method of human disease prevention and/or treatment, the oligonucleotide and/or the pharmaceutical composition according to the present invention is also used in a method for prevention and/or treatment of other subjects including veterinary animals, reptiles, birds, exotic animals and farm animals, including mammals, rodents, and the like. Mammals include for example horses, dogs, pigs, cats, or primates (for example, a monkey, a chimpanzee, or a lemur). Rodents include for example rats, rabbits, mice, squirrels, or guinea pigs.

The oligonucleotide or the pharmaceutical composition according to the invention is used in a method for the prevention and/or treatment of many different diseases, preferably benign or malignant tumors, immunologic diseases, bronchial asthma, heart disease, fibrosis (e.g., liver fibrosis, idiopathic pulmonary fibrosis, liver cirrhosis, kidney cirrhosis, scleroderma), diabetes, wound healing, disorders of the connective tissue (e.g., in heart, blood vessel, bone, joint, eye such as the Marfan or Loeys-Dietz syndrome), psoriasis, eye diseases (e.g., glaucoma, posterior capsular opacification (PCO) also known as secondary cataract), CNS disease (e.g., Alzheimer's disease, Parkinson's disease), coronary atherosclerosis (coronary intervention or coronary artery bypass graft (CABG) surgery or hair loss. A tumor is for example selected from the group of solid tumors, blood born tumors, leukemias, tumor metastasis, hemangiomas, acoustic neuromas, neurofibromas, trachomas, pyogenic granulomas, astrocytoma such as anaplastic astrocytoma, acoustic neuroma, blastoma, Ewing's tumor, craniopharyngloma, ependymoma, medulloblastoma, glioma, glioblastoma, hemangloblastoma, Hodgkins-lymphoma, medullablastoma, leukaemia, melanoma such as primary and/or metastatic melanoma, mesothelioma, myeloma, neuroblastoma, neurofibroma, non-Hodgkins lymphoma, pinealoma, retinoblastoma, sarcoma, seminoma, trachomas, Wilm's tumor, bile duct carcinoma, bladder carcinoma, brain tumor, breast cancer, bronchogenic carcinoma, carcinoma of the kidney, cervical cancer, choriocarcinoma, choroidcarcinoma, cystadenocarcinome, embryonal carcinoma, epithelial carcinoma, esophageal cancer, cervical carcinoma, colon carcinoma, colorectal carcinoma, endometrial cancer, gallbladder cancer, gastric cancer, head cancer, liver carcinoma, lung carcinoma, medullary carcinoma, neck cancer, non-small-cell bronchogenic/lung carcinoma, ovarian cancer, pancreas carcinoma, papillary carcinoma, papillary adenocarcinoma, prostate cancer, small intestine carcinoma, prostate carcinoma, rectal cancer, renal cell carcinoma (RCC, e.g., clear cell RCC, papillary RCC, chromophobe RCC), oncocytoma kidney cancer, transitional cell kidney cancer, retinoblastoma, skin cancer, small-cell bronchogenic/lung carcinoma, squamous cell carcinoma, sebaceous gland carcinoma, testicular carcinoma, and uterine cancer. The oligonucleotide or the pharmaceutical composition of the present invention is not only used in a method for the prevention and/or treatment of a tumor, but likewise on a metastasis.

The antisense oligonucleotides of the present invention are characterized in that they show an unexpected low toxicity (see for example Table 5) and thus, are well tolerated by different organisms. They oligonucleotides show a reasonable distribution in the organism, wherein highest concentrations are measured in the kidney, liver, skin and spleen.

The present invention provides numerous oligonucleotides, which are highly efficient in the reduction and inhibition, respectively, of TGF-beta, in particular TGF-beta1, TGF-beta2 and/or TGF-beta3 expression due to the specific selection of the sequence of the oligonucleotide and the modification of the nucleotide. The following Table 1 shows numerous preferred modified oligonucleotides according to the present invention (bold letters indicate the modified nucleoside). Each oligonucleotides is defined as ASPH and a number, which is defined by a specific sequence and modification of the nucleosides:

SEQ ID NO. Sequence (5′->3′) Modification ASPH 2 GACCAGATGCAGGA LNA 3 + 3 36 3 GCGACCGTGACCAGAT LNA 3 + 3 80 4 GCGCGACCGTGACC LNA 3 + 3 98 5 AGCGCGACCGTGA LNA 2 + 3 111 6 GACCGTGACCAGAT LNA 2 + 2 121 6 GACCGTGACCAGAT LNA 3 + TEG 153 7 CTGCCCGCGGAT LNA 2 + 2 15 8 TCTGCCCGCGGAT LNA 3 + 2 17 9 GGATCTGCCCGCGGA LNA 4 + 3 26 9 GGATCTGCCCGCGGA LNA 3 + 4 27 10 CTTGCTCAGGATCTGCC LNA 4 + 4 37 11 GCTCAGGATCTGCCCGCGGA 2′ O-meth 4 + 4 52 11 GCTCAGGATCTGCCCGCGGA 2′ fluoro 4 + 4 53 12 GGATCGCCTCGAT LNA 3 + 2 112 13 CCGCGGATCGCC LNA 2 + 2 119 14 ACCTCCTTGGCGTAGTA LNA 3 + 3 01 14 ACCTCCTTGGCGTAGTA LNA 4 + 4 02 15 CCTCCTTGGCGTAGTA LNA 3 + 3 03 15 CCTCCTTGGCGTAGTA LNA 4 + 4 04 16 CTCCTTGGCGTAGTA LNA 3 + 3 05 16 CTCCTTGGCGTAGTA LNA 4 + 3 06 16 CTCCTTGGCGTAGTA LNA 3 + 4 07 17 TCCTTGGCGTAGTA LNA 3 + 3 08 18 CAGAAGTTGGCAT LNA 3 + 2 09 18 CAGAAGTTGGCAT LNA 2 + 3 10 19 AAGTGGGCGGGAT — 11 19 AAGTGGGCGGGAT LNA 4 + 4 12 19 AAGTGGGCGGGAT 2′ O-meth 4 + 4 13 19 AAGTGGGCGGGAT 2′ fluoro 4 + 4 14 20 GCGGGATGGCAT LNA 2 + 2 16 21 GAAATCACCTCCG LNA 2 + 3 18 22 AAGTGGGCGGGAT LNA 2 + 3 19 23 TGTAGCGCTGGGT LNA 2 + 3 20 24 CGAAGGAGAGCCA LNA 3 + 2 21 25 TCGCGCTCGCAGGC LNA 3 + 3 22 26 AAGTGGGCGGGATG LNA 3 + 3 23 27 ATGTAGCGCTGGGT LNA 3 + 3 24 28 CGAAGGAGAGCCAT LNA 3 + 3 25 29 GAAAGTGGGCGGGAT LNA 4 + 3 28 30 CGAAGGAGAGCCATT LNA 4 + 3 29 31 CGATCCTCTTGCGCAT LNA 4 + 4 30 32 AAGTGGGCGGGATGGC LNA 4 + 4 31 33 GATGGAAATCACCTCCG LNA 4 + 4 32 34 AAACCTCCTTGGCGTAG LNA 4 + 4 33 35 TAGAAAGTGGGCGGGAT LNA 4 + 4 34 36 GGCGGGATGGCAT LNA 2 + 3 35 37 GGGTCTGTAGAAAGTG LNA 4 + 4 38 38 GAAGGAGAGCCATTC LNA 3 + 4 39 39 CCAGGTTCCTGTCTT LNA 3 + 4 40 40 TCTGATCACCACTGG LNA 3 + 4 41 41 TTTCTGATCACCACTGG LNA 4 + 4 42 42 GTCTGTAGGAGGGCA LNA 4 + 3 43 43 AGTCTGTAGGAGGGCA LNA 4 + 4 44 44 TCTGTAGGAGGGC LNA 2 + 3 45 45 CAGATGCCAGTTTTAAC LNA 4 + 4 46 46 CAAAGTATTTGGTCTCC LNA 4 + 4 47 47 CCTTAAGCCATCCATGA LNA 4 + 4 48 48 GTACTGGCCAGCTAA LNA 4 + 3 49 49 GCCTCGATCCTCTTGCGCAT 2′ O-meth 4 + 4 50 49 GCCTCGATCCTCTTGCGCAT 2′ fluoro 4 + 4 51 50 AAACCTCCTTGGCGTAGTAC 2′ O-meth 4 + 4 54 50 AAACCTCCTTGGCGTAGTAC 2′ fluoro 4 + 4 55 51 GAAAGTGGGCGGGATGGCAT 2′ O-meth 4 + 4 56 51 GAAAGTGGGCGGGATGGCAT 2′ fluoro 4 + 4 57 52 GAATTGCTCGCTTAGGG LNA 3 + 3 60 53 CGTCGCGGTTGCGTTCA LNA 3 + 3 61 54 CGTGGCCTACACCCTGG LNA 3 + 3 62 55 TTCTAAAGCAATAGGCC LNA 3 + 3 63 56 AGAATGGTTAGAGGTTC LNA 3 + 3 64 57 TCTGAACTAGTACCGCC LNA 3 + 3 65 58 CCCATTAATATGACCTC LNA 3 + 3 66 59 TTTAGTTAGAACCCTAA LNA 3 + 3 67 60 CCTCAGATATAGATAAC LNA 3 + 3 68 61 TACTATTATGGCATCCC LNA 3 + 3 69 62 TGCCCACTTGCATACTA LNA 3 + 3 70 63 AGCGTAATTGGTCATCA LNA 3 + 3 71 64 CGTTGGCAGAACATAGA LNA 3 + 3 72 65 GGGATACTGTCTAGACC LNA 3 + 3 73 66 ATTGGCAACTCGTTTGA LNA 3 + 3 74 67 CGTCAGGCTAATATTC LNA 3 + 3 75 68 GGATGACTCCCTAGAC LNA 3 + 3 76 69 GTCGCGGTTGCGTTCA LNA 3 + 3 77 70 CTCGGTACTCGGTCGG LNA 3 + 3 78 71 GGTTCGGTCCTGCCTT LNA 3 + 3 79 72 AATAGGCCGCATCCAA LNA 3 + 3 81 73 AACTAGTACCGCCTTT LNA 3 + 3 82 74 TCGGTCATATAATAAC LNA 3 + 3 83 75 AGACCGTCAGGCTAA LNA 3 + 3 84 76 GTCGCGGTTGCGTTC LNA 3 + 3 85 77 TTCCACTGCGGCGCT LNA 3 + 3 86 78 AAGGAGCGGTTCGGT LNA 3 + 3 87 79 CTCGGGTGCGGAGTG LNA 3 + 3 88 80 CTGACTTTGGCGAGT LNA 3 + 3 89 81 GATAGGAACGGTACG LNA 3 + 3 90 82 CACTTTGGATTCCCG LNA 3 + 3 91 83 GTCGCGGTTGCGTT LNA 3 + 3 92 84 TACACCCTGGCGGG LNA 3 + 3 93 85 CTCGGTACTCGGTC LNA 3 + 3 94 86 AGGAGCGGTTCGGT LNA 3 + 3 95 87 GTCTCGGGTGCGGA LNA 3 + 3 96 88 TACGGGACGGGCAG LNA 3 + 3 97 89 CGTCGCTCCTCTCG LNA 3 + 3 99 90 TAGCGCTGGGTTGG LNA 3 + 3 100 91 AAGCAATAGGCCGC LNA 3 + 3 101 92 TACGGGCATGCTCC LNA 3 + 3 102 93 AGGCGCGGGATAGG LNA 3 + 3 103 94 TTTGGATTCCCGCC LNA 3 + 3 104 95 ACCACTAGAGCACC LNA 3 + 3 105 96 GCGTTGGCAGAACA LNA 3 + 3 106 97 TTGCTCGCTTAGG LNA 2 + 3 107 98 GTCGCGGTTGCGT LNA 3 + 2 108 99 GGCGCTCGGTACT LNA 2 + 3 109 100 ATCTGAACTCGGC LNA 3 + 2 110 101 CGGTTGGTCTGTT LNA 2 + 3 113 102 TCCACCCTAGATC LNA 2 + 3 114 103 CTAGTACCGCCTT LNA 2 + 3 115 104 GGTCGGCAGTCAA LNA 3 + 2 116 105 CTTGCGACACCC LNA 2 + 2 117 106 GAGCGGTTCGGT LNA 2 + 2 118 107 ACACAGTAGTGCAT LNA 2 + 2 120 108 GGGTCTGTAGAAAG LNA 2 + 2 122 108 GGGTCTGTAGAAAG LNA 3 + TEG 154 109 GGTTGGAGATGTTA LNA 2 + 2 123 109 GGTTGGAGATGTTA LNA 3 + TEG 155 110 TGGGTTGGAGATGT LNA 2 + 2 124 110 TGGGTTGGAGATGT LNA 3 + TEG 156 111 GCTGGGTTGGAGAT LNA 2 + 2 125 111 GCTGGGTTGGAGAT LNA 3 + TEG 157 112 GCGCTGGGTTGGAG LNA 2 + 2 126 112 GCGCTGGGTTGGAG LNA 3 + TEG 158 113 AGCGCTGGGTTGGA LNA 2 + 2 127 113 AGCGCTGGGTTGGA LNA 3 + TEG 159 114 TAGCGCTGGGTTGG LNA 2 + 2 128 114 TAGCGCTGGGTTGG LNA 3 + TEG 160 115 GTAGCGCTGGGTTG LNA 2 + 2 129 115 GTAGCGCTGGGTTG LNA 3 + TEG 161 116 GATGTAGCGCTGGG LNA 2 + 2 130 116 GATGTAGCGCTGGG LNA 3 + TEG 162 117 CCATTCGCCTTCTG LNA 2 + 2 131 117 CCATTCGCCTTCTG LNA 3 + TEG 163 118 GAGAGCCATTCGCC LNA 2 + 2 132 118 GAGAGCCATTCGCC LNA 3 + TEG 164 119 AGCAGGGACAGTGT LNA 2 + 2 133 119 AGCAGGGACAGTGT LNA 3 + TEG 165 120 GCAGGAGATGTGGG LNA 2 + 2 134 120 GCAGGAGATGTGGG LNA 3 + TEG 166 121 CGGTTGGTCTGTTG LNA 2 + 2 135 121 CGGTTGGTCTGTTG LNA 3 + TEG 167 122 CCGGTTGGTCTGTT LNA 2 + 2 136 122 CCGGTTGGTCTGTT LNA 3 + TEG 168 123 GCCGGTTGGTCTGT LNA 2 + 2 137 123 GCCGGTTGGTCTGT LNA 3 + TEG 169 124 AGTTGGCATTGTAC LNA 2 + 2 138 124 AGTTGGCATTGTAC LNA 3 + TEG 170 125 GGTTAGAGGTTCTA LNA 2 + 2 139 125 GGTTAGAGGTTCTA LNA 3 + TEG 171 126 ATGGTTAGAGGTTC LNA 2 + 2 140 126 ATGGTTAGAGGTTC LNA 3 + TEG 172 127 AGAATGGTTAGAGG LNA 2 + 2 141 127 AGAATGGTTAGAGG LNA 3 + TEG 173 128 AGAGAATGGTTAGA LNA 2 + 2 142 128 AGAGAATGGTTAGA LNA 3 + TEG 174 129 CGTTGTCGTCGTCA LNA 2 + 2 143 129 CGTTGTCGTCGTCA LNA 3 + TEG 175 130 ACCAAGGCTCTCTT LNA 2 + 2 144 130 ACCAAGGCTCTCTT LNA 3 + TEG 176 131 GCTTCTTGTCTCTC LNA 2 + 2 145 131 GCTTCTTGTCTCTC LNA 3 + TEG 177 132 GGAACGGTACGTAC LNA 2 + 2 146 132 GGAACGGTACGTAC LNA 3 + TEG 178 133 TAGGAACGGTACGT LNA 2 + 2 147 133 TAGGAACGGTACGT LNA 3 + TEG 179 134 GGGATAGGAACGGT LNA 2 + 2 148 134 GGGATAGGAACGGT LNA 3 + TEG 180 135 CGCGGGATAGGAAC LNA 2 + 2 149 135 CGCGGGATAGGAAC LNA 3 + TEG 181 136 AGGCGCGGGATAGG LNA 2 + 2 150 136 AGGCGCGGGATAGG LNA 3 + TEG 182 137 GTCAAGCTGGATGG LNA 2 + 2 151 137 GTCAAGCTGGATGG LNA 3 + TEG 183 138 TCTGTAGGAGGGC ENA 2 + 3 184 139 GACCAGATGCAGGA ENA 3 + 3 185 140 CTCCTTGGCGTAGTA ENA 3 + 3 186 141 CCTCCTTGGCGTAGTA ENA 3 + 3 187 142 CAGATGCCAGTTTTAAC ENA 4 + 4 188 143 AGCGTAATTGGTCATCA ENA 3 + 3 189 146 AGTATTTGGTCTCC LNA 3 + 3 190 147 AAGTATTTGGTCTC LNA 3 + 3 191 148 AAGTATTTGGTCTCC LNA 3 + 3 192 149 CAAAGTATTTGGTCTCC LNA 3 + 3 193 150 AGCTCGTCCCTCCTCCC LNA 3 + 3 1000 151 GAGGGCTGGTCCGGAAT LNA 3 + 3 1001 152 CGAGGGCTGGTCCGGAA LNA 3 + 3 1002 153 GAGGGCGGCATGGGGGA LNA 3 + 3 1003 154 GCGGGTGCTGTTGTACA LNA 3 + 3 1004 155 CGCGGGTGCTGTTGTAC LNA 3 + 3 1005 156 GTCGCGGGTGCTGTTGT LNA 3 + 3 1006 157 GGTCGCGGGTGCTGTTG LNA 3 + 3 1007 158 CCGGTCGCGGGTGCTGT LNA 3 + 3 1008 159 CCCGGTCGCGGGTGCTG LNA 3 + 3 1009 160 AGCACGCGGGTGACCTC LNA 3 + 3 1010 161 TTAGCACGCGGGTGACC LNA 3 + 3 1011 162 GGGCTCGTGGATCCACT LNA 3 + 3 1012 163 CCTTGGGCTCGTGGATC LNA 3 + 3 1013 164 TGGCATGGTAGCCCTTG LNA 3 + 3 1014 165 CGAGGGCTGGTCCGGA LNA 3 + 3 1015 166 GCGGGTGCTGTTGTAC LNA 3 + 3 1016 167 GCACGCGGGTGACCTC LNA 3 + 3 1017 168 CCTTGGGCTCGTGGAT LNA 3 + 3 1018 169 GGCATGGTAGCCCTTG LNA 3 + 3 1019 170 GGGTGCTGTTGTAC LNA 3 + 3 1020 171 TCGCGGGTGCTGTT LNA 3 + 3 1021 172 GTCGCGGGTGCTGT LNA 3 + 3 1022 173 CTCGTGGATCCACT LNA 3 + 3 1023 174 ATGGTAGCCCTTGG LNA 3 + 3 1024 175 TGGCATGGTAGCCC LNA 3 + 3 1025 176 GAAGTTGGCATGGT LNA 3 + 3 1026 177 TCGCGGGTGCTGT LNA 2 + 3 1027 178 CACCCGGTCGCGG LNA 2 + 3 1028 179 CCACCCGGTCGCG LNA 2 + 3 1029 180 CGCCAGGAATTGT LNA 3 + 2 1030 181 GGCTCGTGGATCC LNA 2 + 3 1031 182 TGGGCTCGTGGAT LNA 2 + 3 1032 183 GCATGGTAGCCCT LNA 2 + 3 1033 184 AGTTGGCATGGTA LNA 2 + 3 1034 185 TTGCAGGAGCGCA LNA 2 + 3 1035 186 ATTAGCACGCGGGTGAC LNA 3 + 3 1036 187 ACCATTAGCACGCGGGT LNA 3 + 3 1037 188 CACCATTAGCACGCGGG LNA 3 + 3 1038 189 CCACCATTAGCACGCGG LNA 3 + 3 1039 190 TCCACCATTAGCACGCG LNA 3 + 3 1040 191 TCCACCTTGGGCTTGCG LNA 3 + 3 1041 192 TTAGCACGCGGGTGAC LNA 3 + 3 1042 193 ACCATTAGCACGCGGG LNA 3 + 3 1043 194 CACCATTAGCACGCGG LNA 3 + 3 1044 195 CACCATTAGCACGCG LNA 3 + 3 1045 196 GCGGCACGCAGCACG LNA 3 + 3 1046 197 TCGATGCGCTTCCG LNA 3 + 3 1047 198 TAGCACGCGGGTGA LNA 3 + 3 1048 199 ATTAGCACGCGGGT LNA 3 + 3 1049 200 CATTAGCACGCGGG LNA 3 + 3 1050 201 ACCATTAGCACGCG LNA 3 + 3 1051 202 CACCATTAGCACGC LNA 3 + 3 1052 203 CCACCATTAGCACG LNA 3 + 3 1053 204 TCCACCATTAGCAC LNA 3 + 3 1054 205 GACCTTGCTGTACT LNA 3 + 3 1055 206 GGACCTTGCTGTAC LNA 3 + 3 1056 207 AGGACCTTGCTGTA LNA 3 + 3 1057 208 CGGCACGCAGCACG LNA 3 + 3 1058 209 ACCTTGGGCTTGCG LNA 3 + 3 1059 210 TTAGCACGCGGGT LNA 3 + 2 1060 211 ACCATTAGCACGC LNA 3 + 2 1061 212 CGGCACGCAGCAC LNA 3 + 2 1062 213 CACCAGCTCCATGTCGA LNA 3 + 3 1063 214 TCGCGGGTGCTGTTGTA LNA 3 + 3 1064 215 GTGTCCAGGCTCCAAAT LNA 3 + 3 1065 215 GTGTCCAGGCTCCAAAT LNA 4 + 2 1066 216 GCTCGTCCCTCCTCCC LNA 3 + 3 1067 217 ACCAGCTCGTCCCTCC LNA 3 + 3 1068 218 GGAGGCCCCGCCCCTG LNA 3 + 3 1069 219 CATGGGGGAGGCGGCG LNA 3 + 3 1070 219 CATGGGGGAGGCGGCG 3LNA + 9N + 1LNA + 1071 1N + 2LNA 220 ACCAGCTCCATGTCGA LNA 3 + 3 1072 221 GGTCGCGGGTGCTGTT LNA 3 + 3 1073 222 GGACCTTGCTGTACTG LNA 3 + 3 1074 222 GGACCTTGCTGTACTG LNA 4 + 2 1075 223 TCCACCTTGGGCTTGC LNA 3 + 3 1076 224 AGCTCGTCCCTCCTC LNA 3 + 3 1077 225 CCAGCTCGTCCCTCC LNA 3 + 3 1078 226 GAGGGCTGGTCCGGA LNA 3 + 3 1079 227 TCCCGAGGGCTGGTC LNA 3 + 3 1080 228 CGGCATGGGGGAGGC LNA 2 + 4 1081 229 CAGCTCCATGTCGAT LNA 3 + 3 1082 230 ACCAGCTCCATGTCG LNA 3 + 3 1083 231 TCGCGGGTGCTGTTG LNA 3 + 3 1084 232 GTCGCGGGTGCTGTT LNA 3 + 3 1085 233 GGTCGCGGGTGCTGT LNA 3 + 3 1086 234 AGCACGCGGGTGACC LNA 3 + 3 1087 235 TAGCACGCGGGTGAC LNA 3 + 3 1088 236 CATTAGCACGCGGGT LNA 3 + 3 1089 237 TCCACCATTAGCACG LNA 3 + 3 1090 238 CCAGGAATTGTTGCT LNA 4 + 2 1091 239 TTGGGCTCGTGGATC LNA 3 + 3 1092 240 CTTGGGCTCGTGGAT LNA 3 + 3 1093 241 TTGGCATGGTAGCCC LNA 3 + 3 1094 242 GAAGTTGGCATGGTA LNA 3 + 3 1095 243 AGAAGTTGGCATGGT LNA 3 + 3 1096 244 TGTCCAGGCTCCAAA LNA 4 + 2 1097 245 AGGACCTTGCTGTAC LNA 3 + 3 1098 246 CACCTTGGGCTTGCG LNA 4 + 2 1099 246 CACCTTGGGCTTGCG 1LNA + 1N + 2LNA + 1100 8N + 1LNA + 1N + 1LNA 247 AGCTCGTCCCTCCT LNA 3 + 3 1101 248 CAGCTCGTCCCTCC LNA 3 + 3 1102 249 ACCAGCTCGTCCCT LNA 3 + 3 1103 250 CCCGAGGGCTGGTC LNA 3 + 3 1104 251 GCGGCATGGGGGAG LNA 2 + 4 1105 252 GTCTTGCAGGTGGA LNA 3 + 3 1106 253 TCGATGCGCTTCCG LNA 2 + 4 1107 253 TCGATGCGCTTCCG LNA 2 + 3 1108 253 TCGATGCGCTTCCG 2LNA + 8N + 2LNA + 1109 1N + 1LNA 253 TCGATGCGCTTCCG 2LNA + 9N + 1LNA + 1110 1N + 1LNA 253 TCGATGCGCTTCCG 2LNA + 8N + 1LNA + 1111 2N + 1LNA 254 GGACAGGATCTGGC LNA 4 + 2 1112 255 ACCTCCCCCTGGCT LNA 3 + 3 1113 256 ACCATTAGCACGCG LNA 4 + 2 1114 256 ACCATTAGCACGCG 3LNA + 8N + 1LNA + 1115 1N + 1LNA 257 CAGCAGTTCTTCTC LNA 2 + 4 1116 258 TACAGCTGCCGCAC LNA 3 + 3 1117 259 AGTTGGCATGGTAG LNA 3 + 3 1118 259 AGTTGGCATGGTAG LNA 4 + 2 1119 260 AAGTTGGCATGGTA LNA 3 + 3 1120 261 GAAGTTGGCATGGT LNA 4 + 2 1121 262 TCCAGGCTCCAAAT LNA 3 + 3 1122 263 ACCTTGCTGTACTG LNA 3 + 3 1123 263 ACCTTGGGCTTGCG LNA 4 + 2 1124 263 ACCTTGGGCTTGCG LNA 3 + 2 1125 263 ACCTTGGGCTTGCG 3LNA + 8N + 1LNA + 1126 1N + 1LNA 263 ACCTTGGGCTTGCG 2LNA + 9N + 1LNA + 1127 1N + 1LNA 263 ACCTTGGGCTTGCG 2LNA + 8N + 2LNA + 1128 1N + 1LNA 264 TTGCAGGAGCGCAC LNA 3 + 3 1129 265 GCAGAAGTTGGCAT LNA 4 + 2 1130 266 CGGGTGCTGTTGTA LNA 3 + 3 1131 266 CGGGTGCTGTTGTA LNA 2 + 4 1132 267 CCCAGCGGCAACGGAAA LNA 3 + 3 1133 268 CAAGAGGTCCCCGCGCC LNA 3 + 3 1134 269 GCGTCCCCGGCGGCAAA LNA 3 + 3 1135 270 GGTCGGCGACTCCCGAG LNA 3 + 3 1136 271 TCGGAGAGAGATCCGTC LNA 3 + 3 1137 272 ATCCCACGGAAATAACC LNA 3 + 3 1138 273 CTCAGTATCCCACGGAA LNA 3 + 3 1139 274 ACTGCCGAGAGCGCGAA LNA 3 + 3 1140 275 CTGATGTGTTGAAGAAC LNA 3 + 3 1141 276 TGAGGTATCGCCAGGAA LNA 3 + 3 1142 277 ACTGCCGCACAACTCCG LNA 3 + 3 1143 278 CGGCCCACGTAGTACAC LNA 3 + 3 1144 279 CCCAGCGGCAACGGAA LNA 3 + 3 1145 280 TCGCGCCAAGAGGTCC LNA 3 + 3 1146 281 GGTCGGCGACTCCCGA LNA 3 + 3 1147 282 GTCGGAGAGAGATCCG LNA 3 + 3 1148 283 TCAGTATCCCACGGAA LNA 3 + 3 1149 284 CGAGAGCGCGAACAGG LNA 3 + 3 1150 285 ACTGCCGAGAGCGCGA LNA 3 + 3 1151 286 GGCGTCAGCACCAGTA LNA 3 + 3 1152 287 GGTTTCCACCATTAGC LNA 3 + 3 1153 288 GAGGTATCGCCAGGAA LNA 3 + 3 1154 289 AACCACTGCCGCACAA LNA 3 + 3 1155 290 CGGCCCACGTAGTACA LNA 3 + 3 1156 291 CGGCGGCTCGTCTCA LNA 3 + 3 1157 292 CCCAGCGGCAACGGA LNA 3 + 3 1158 293 TCGCGCCAAGAGGTC LNA 3 + 3 1159 294 CGTCGCGCCAAGAGG LNA 3 + 3 1160 295 GGAGCAAGCGTCCCC LNA 3 + 3 1161 296 GTGCGCCCGAGGTCT LNA 3 + 3 1162 297 GTCTAGGATGCGCGG LNA 3 + 3 1163 298 CAGTATCCCACGGAA LNA 3 + 3 1164 299 CCGAGAGCGCGAACA LNA 3 + 3 1165 300 GGCGTCAGCACCAGT LNA 3 + 3 1166 301 GTTGCTGAGGTATCG LNA 3 + 3 1167 302 ACCACTGCCGCACAA LNA 3 + 3 1168 303 CGGCCCACGTAGTAC LNA 3 + 3 1169 304 CTCGGCGACTCCTT LNA 3 + 3 1170 305 AGCGGCAACGGAAA LNA 3 + 3 1171 306 TCGCGCCAAGAGGT LNA 3 + 3 1172 307 TCCCCGGCGGCAAA LNA 3 + 3 1173 308 TGCGCCCGAGGTCT LNA 3 + 3 1174 309 GTCTAGGATGCGCG LNA 3 + 3 1175 310 GGTCGGAGAGAGAT LNA 3 + 3 1176 311 CACGGAAATAACCT LNA 3 + 3 1177 312 AGAGCGCGAACAGG LNA 3 + 3 1178 313 ATAGTCCCGCGGCC LNA 3 + 3 1179 314 TAGTAGTCGGCCTC LNA 3 + 3 1180 315 ATAGATTTCGTTGT LNA 3 + 3 1181 316 GAGGTATCGCCAGG LNA 3 + 3 1182 317 GCCGCACAACTCCG LNA 3 + 3 1183 318 TCGCGCCAAGAGG LNA 2 + 3 1184 319 AAGCGTCCCCGGC LNA 3 + 2 1185 320 GACGCCGTGTAGG LNA 3 + 2 1186 321 GTCGGCGACTCCC LNA 2 + 3 1187 322 TGCGCCCGAGGTC LNA 3 + 2 1188 323 GTCGGAGAGAGAT LNA 3 + 2 1189 324 TCCCACGGAAATA LNA 3 + 2 1190 325 TGCCGAGAGCGCG LNA 2 + 3 1191 326 TAGTCCCGCGGCC LNA 3 + 2 1192 327 TAGTAGTCGGCCT LNA 3 + 2 1193 328 CATAGATTTCGTT LNA 2 + 3 1194 329 TTTAACTTGAGCC LNA 3 + 2 1195 330 GAGGTATCGCCAG LNA 3 + 2 1196 331 ACTCCGGTGACAT LNA 2 + 3 1197 332 GCCCACGTAGTAC LNA 2 + 3 1198 333 TCGGCGACTCCC LNA 2 + 2 1199 334 GTCGGCGACTCC LNA 2 + 2 1200 337 CAGGAAGCGCTGGCAAC LNA 3 + 3 2000 338 GGTGCATGAACTCACTG LNA 3 + 3 2001 339 GTCCCCTAATGGCTTCC LNA 3 + 3 2002 340 ATCTGTCCCCTAATGGC LNA 3 + 3 2003 341 CCGGGTGCTGTTGTAAA LNA 3 + 3 2004 342 CCTGGATCATGTCGAAT LNA 3 + 3 2005 343 CCCTGGATCATGTCGAA LNA 3 + 3 2006 344 GTAGCACCTGCTTCCAG LNA 3 + 3 2007 345 GGGCTTTCTAAATGAC LNA 3 + 3 2008 346 TGACTCCCAGCAGGCC LNA 3 + 3 2009 347 GTGCATGAACTCACTG LNA 3 + 3 2010 348 GGTGCATGAACTCACT LNA 3 + 3 2011 349 ATCTGTCCCCTAATGG LNA 3 + 3 2012 350 CGGGTGCTGTTGTAAA LNA 3 + 3 2013 351 CCGGGTGCTGTTGTAA LNA 3 + 3 2014 352 CCTGGATCATGTCGAA LNA 3 + 3 2015 353 CCCTGGATCATGTCGA LNA 3 + 3 2016 354 TTTGAATTTGATTTCC LNA 3 + 3 2017 355 GGGCCTGAGCAGAAGT LNA 3 + 3 2018 356 GGGGGCTTTCTAAAT LNA 3 + 3 2019 357 TTTGTTTACACTTCC LNA 3 + 3 2020 358 CCAGCTAAAGGTGGG LNA 3 + 3 2021 359 ATGGCTGGGTCCCAA LNA 3 + 3 2022 360 GAGTTTTTCCTTAGG LNA 3 + 3 2023 361 AGGGGTGGCAAGGCA LNA 3 + 3 2024 362 TGACTCCCAGCAGGC LNA 3 + 3 2025 363 GAAGCGCTGGCAACC LNA 3 + 3 2026 364 GTGCATGAACTCACT LNA 3 + 3 2027 365 GTGGTGCAAGTGGAC LNA 3 + 3 2028 366 CTAATGGCTTCCACC LNA 3 + 3 2029 367 CCCCTAATGGCTTCC LNA 3 + 3 2030 368 ATCTGTCCCCTAATG LNA 3 + 3 2031 369 GATCTGTCCCCTAAT LNA 3 + 3 2032 370 AGATCTGTCCCCTAA LNA 3 + 3 2033 371 GGTGCTGTTGTAAAG LNA 3 + 3 2034 372 CCGGGTGCTGTTGTA LNA 3 + 3 2035 373 GATCATGTCGAATTT LNA 3 + 3 2036 374 CCTGGATCATGTCGA LNA 3 + 3 2037 375 CCCTGGATCATGTCG LNA 3 + 3 2038 376 GATTTCCATCACCTC LNA 3 + 3 2039 377 TTGAATTTGATTTCC LNA 3 + 3 2040 378 AGCAGTTCTCCTCCA LNA 3 + 3 2041 379 GCCTGAGCAGAAGTT LNA 3 + 3 2042 380 GGGCAAGGGCCTGAG LNA 3 + 3 2043 381 CCCACACTTTCTTTA LNA 3 + 3 2044 382 TAGCACCTGCTTCCA LNA 3 + 3 2045 383 CGGGGGCTTTCTAA LNA 3 + 3 2046 384 CCATTCATGCTTTC LNA 3 + 3 2047 385 AAGCGCTGGCAACC LNA 3 + 3 2048 386 ACCAGAGCCCTTTG LNA 3 + 3 2049 387 CCCCTAATGGCTTC LNA 3 + 3 2050 388 GTCCCCTAATGGCT LNA 3 + 3 2051 389 ATCTGCCCCTAAT LNA 3 + 3 2052 390 AGATCTGTCCCCTA LNA 3 + 3 2053 391 CGGGTGCTGTTGTA LNA 3 + 3 2054 392 ATCATGTCGAATTT LNA 3 + 3 2055 393 CCCTGGATCATGTC LNA 3 + 3 2056 394 CCTTTGAATTTGAT LNA 3 + 3 2057 395 TTGCGGAAGCAGTA LNA 3 + 3 2058 396 GCCTGAGCAGAAGT LNA 3 + 3 2059 397 GGGGGCTTTCTAA LNA 2 + 3 2060 398 AGCGCTGGCAACC LNA 2 + 3 2061 399 CCCCTAATGGCTT LNA 2 + 3 2062 399 CCCCTAATGGCTT LNA 3 + 2 2063 400 TCCCCTAATGGCT LNA 3 + 2 2064 401 TCATGTCGAATTT LNA 2 + 3 2065 402 ATCATGTCGAATT LNA 3 + 2 2066

Table 1 shows the nucleic acid sequences of selected oligonucleotides of the present invention as well as the modifications of the nucleotides, wherein LNA 4+4 means 4×LNAs at the 5′- and 3′-end of the oligonucleotide are modified, wherein LNA 4+3 means 4×LNAs at the 5′-end and 3×LNAs at the 3′-end of the oligonucleotide are modified, wherein LNA 3+4 means 3×LNAs at the 5′-end and 4×LNAs at the 3′-end of the oligonucleotide are modified, wherein LNA 3+3 means 3×LNAs at the 5′- and 3′-end of the oligonucleotide are modified, wherein LNA 3+2 means 3×LNAs at the 5′-end and 2×LNAs at the 3′-end of the oligonucleotide are modified, wherein LNA 2+3 means 2×LNAs at the 5′-end and 3×LNAs at the 3′-end of the oligonucleotide are modified, wherein LNA 2+2 means 2×LNAs at the 5′- and 3′-end of the oligonucleotide are modified. Alternatively, some oligonucleotides comprise ENA 4+4, i.e., 4×ENA at the 5′- and 3′-end of the oligonucleotide are modified, or ENA 3+3, i.e, 3×ENA at the 5′- and 3′-end of the oligonucleotide are modified. Further oligonucleotides comprise 2′O-meth 4+4, wherein the oligonucleotide comprises 4×2′O-methyl modified nucleotides at the 5′- and 3′-end of the oligonucleotide, or comprises 2′ fluoro 4+4, wherein the oligonucleotide comprises 4×2′fluoro modified nucleotides at the 5′- and 3′-end. Oligonucleotides comprising LNA 3+TEG comprise 3×LNAs at the 5′-end and one triethylene glycol (TEG) at the 3′-end of the oligonucleotide. Some oligonucleotides comprise LNAs which are not arranged in a row but are separated by an unlocked nucleoside having for example the sequences 3LNA+9N+1LNA+1N+2LNA, 1LNA+1N+2LNA+8N+1LNA+1N+1LNA, 2LNA+8N+2LNA+1N+1LNA, 2LNA+9N+1LNA+1N+1LNA, 2LNA+8N+1LNA+2N+1LNA, 3 LNA+8N+1LNA+1N+1LNA, 3 LNA+8N+1LNA+1N+1LNA, 2LNA+9N+1LNA+1N+1LNA, or 2LNA+8N+2LNA+1N+1LNA, wherein “N” is a nucleoside without locked modification. “ASPH” in combination with a number refers to the different oligonucleotides and their different modifications as described in Table 1. These modified oligonucleotides were tested e.g. in experiments shown in the following examples. The antisense oligonucleotides of the present invention can be described differently, e.g., ASPH47, ASPH0047, ASPH_47 or ASPH_0047 referring to the same oligonucleotide.

For the purpose of clarity and a concise description, features are described herein as part of the same or separate embodiments, however, it will be appreciated that the scope of the invention may include embodiments having combinations of all or some of the features described.

The following examples will serve to further illustrate the present invention without, at the same time, however, constituting any limitation thereof. On the contrary, it is to be clearly understood that the scope of the present invention refers to various other embodiments, modifications, and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the invention.

EXAMPLES

In the following examples, the effect of the oligonucleotides listed in Table 1 has been tested in view of the reduction and inhibition, respectively, of TGF-beta1 and/or TGF-beta2 expression. SEQ ID NO. 144 (T-LNA: CGGCATGTCTATTTTGTA, wherein 3× nucleotides at the 5′- and 3′-end are LNAs) and SEQ ID NO. 145 (scr-LNA: CGTTTAGGCTATGTACTT, wherein 3× nucleotides at the 5′- and 3′-end are LNAs) are used as control oligonucleotides, wherein SEQ ID NO. 145 (negative control) is the scrambled form of SEQ ID NO. 144 (positive control). The cells were either transfected in the presence of a transfecting agent (e.g., Lipofectamine), or in the absence of any transfecting agent (which is defined as gymnotic transfection or unassisted transfection or gymnotic delivery). In case of gymnotic delivery the entry of the oligonucleotide into the cell solely depends on the interaction of the oligonucleotide with the cell (no compound/agent supports the entry). Therefore, gymnotic transfection or gymnotic delivery is considered to reflect better conditions of the in vivo settings.

Example 1

Human A172 glioma cells were transfected with 10 nM of ASPH01, ASPH02, ASPH03, ASPH04, ASPH05, ASPH06, ASPH07, ASPH08, ASPH09, ASPH10, ASPH11, ASPH12, ASPH13, ASPH14, ASPH15, ASPH16, ASPH17, ASPH18, ASPH19, ASPH20, ASPH21, ASPH22, ASPH24, ASPH25, ASPH26, ASPH27, ASPH29, ASPH30, ASPH31, ASPH32, ASPH33, ASPH34, ASPH35, ASPH36, ASPH37, ASPH38, ASPH39, ASPH40, ASPH41, ASPH42, ASPH43, ASPH44, ASPH45, ASPH46, ASPH47, ASPH48, ASPH49, ASPH50, ASPH51, ASPH52, ASPH53, and ASPH54 (see FIG. 3a (i), FIG. 3a (ii), FIG. 3a (iii)); ASPH36, ASPH60, ASPH61, ASPH62, ASPH63, ASPH64, ASPH65, ASPH66, ASPH67, ASPH68, ASPH69, ASPH70, ASPH71, ASPH72, ASPH73, ASPH74, ASPH75, ASPH76, ASPH77, ASPH78, ASPH79, ASPH80, ASPH81, ASPH82, ASPH83, ASPH84, ASPH85, ASPH86, ASPH87, ASPH88, ASPH89, ASPH90, ASPH91, ASPH92, ASPH93, ASPH94, ASPH95, ASPH96, ASPH97, ASPH98, ASPH99, ASPH100, ASPH101, ASPH102, ASPH103, ASPH104, ASPH105, ASPH106, ASPH107, ASPH108, ASPH109, ASPH110, ASPH111, ASPH112, ASPH113, ASPH114, ASPH115, ASPH116, ASPH117, ASPH118, and ASPH119 (see FIG. 3b (i), FIG. 3b (ii), FIG. 3b (iii)), or ASPH36, ASPH71, ASPH73, ASPH120, ASPH121, ASPH122, ASPH123, ASPH124, ASPH125, ASPH126, ASPH127, ASPH128, ASPH129, ASPH130, ASPH131, ASPH132, ASPH133, ASPH134, ASPH135, ASPH136, ASPH137, ASPH138, ASPH139, ASPH140, ASPH141, ASPH142, ASPH143, ASPH145, ASPH146, ASPH147, ASPH148, ASPH149, ASPH150, ASPH151, ASPH152, ASPH153, ASPH154, ASPH155, ASPH157, ASPH158, ASPH160, ASPH161, ASPH162, ASPH163, ASPH164, ASPH165, ASPH166, ASPH167, ASPH168, ASPH169, ASPH170, ASPH171, ASPH172, ASPH173, ASPH174, ASPH175, ASPH176, ASPH177, ASPH178, ASPH179, ASPH180, ASPH181, ASPH182, and ASPH183 (see FIG. 3c (i), FIG. 3c (ii), FIG. 3c (iii)), and the controls of SEQ ID NO. 144 and 145, respectively, in the presence of a transfecting agent. The expression of TGF-beta1 and TGF-beta2 mRNA was determined 24 h after transfection. Significant reduction of the expression of TGF-beta1 and TGF-beta2 mRNA is demonstrated in FIG. 3a (i), FIG. 3a (ii), FIG. 3a (iii), FIG. 3b (i), FIG. 3b (ii), FIG. 3b (iii), and FIG. 3c (i), FIG. 3c (ii), FIG. 3c (iii). The dual TGF-beta1 and TGF-beta2 reactive oligonucleotides ASPH01, ASPH02, ASPH03, ASPH04, ASPH05, ASPH06, ASPH07, ASPH08 and ASPH09 show a significant reduction of the expression of both TGF-beta1 and TGF-beta2 mRNA, while the selective TGF-beta2 oligonucleotides significantly inhibit TGF-beta2 mRNA expression.

Example 2

Human Panc-1 pancreatic cancer cells were transfected with 10 nM of ASPH01, ASPH02, ASPH03, ASPH04, ASPH05, ASPH06, ASPH07, ASPH08, ASPH12, ASPH14, ASPH17, ASPH18, ASPH20, ASPH21, ASPH22, ASPH24, ASPH25, ASPH26, ASPH27, ASPH29, ASPH30, ASPH31, ASPH32, ASPH33, ASPH35, ASPH36, ASPH37, ASPH38, ASPH39, ASPH40, ASPH41, ASPH42, ASPH43, ASPH44, ASPH45, ASPH46, ASPH47, ASPH48, ASPH49, ASPH50, ASPH51, and ASPH52 (see FIG. 4a (i), and FIG. 4a (ii); ASPH36, ASPH60, ASPH61, ASPH62, ASPH63, ASPH64, ASPH65, ASPH66, ASPH67, ASPH68, ASPH69, ASPH70, ASPH71, ASPH72, ASPH73, ASPH74, ASPH75, ASPH76, ASPH77, ASPH78, ASPH79, ASPH80, ASPH81, ASPH82, ASPH83, ASPH84, ASPH85, ASPH86, ASPH87, ASPH88, ASPH89, ASPH90, ASPH91, ASPH92, ASPH93, ASPH94, ASPH96, ASPH97, ASPH98, ASPH99, ASPH100, ASPH101, ASPH102, ASPH103, ASPH104, ASPH105, ASPH106, ASPH107, ASPH108, ASPH109, ASPH110, ASPH111, ASPH112, ASPH113, ASPH114, ASPH115, ASPH116, ASPH117, ASPH118, and ASPH119 (see FIG. 4b (i), FIG. 4b (ii), and FIG. 4b (iii), or ASPH36, ASPH71, ASPH73, ASPH120, ASPH121, ASPH122, ASPH127, ASPH128, ASPH129, ASPH130, ASPH131, ASPH132, ASPH133, ASPH135, ASPH136, ASPH137, ASPH139, ASPH141, ASPH142, ASPH143, ASPH145, ASPH146, ASPH147, ASPH149, ASPH150, ASPH151, ASPH152, ASPH153, ASPH154, ASPH155, ASPH157, ASPH160, ASPH161, ASPH162, ASPH163, ASPH164, ASPH165, ASPH166, ASPH167, ASPH168, ASPH169, ASPH170, ASPH171, ASPH172, ASPH173, ASPH174, ASPH175, ASPH176, ASPH177, ASPH178, ASPH179, ASPH180, ASPH181, ASPH182, and ASPH183 (see FIG. 4c (i), FIG. 4c (ii), and FIG. 4c (iii)) and the controls of SEQ ID NO. 144 and 145, respectively, in the presence of a transfecting agent. The expression of TGF-beta1 and TGF-beta2 mRNA was determined 24 h after transfection. Significant reduction of the expression of TGF-beta1 and TGF-beta2 mRNA is demonstrated in 4 a(i), FIG. 4a (ii), FIG. 4b (i), FIG. 4b (ii), FIG. 4b (iii), and FIG. 4c (i), FIG. 4c (ii), and FIG. 4c (iii). The dual TGF-beta1 and TGF-beta2 reactive oligonucleotides ASPH01, ASPH02, ASPH03, ASPH04, ASPH05, ASPH06, ASPH07, and ASPH08, respectively, show again a significant reduction of the expression of both TGF-beta1 and TGF-beta2 mRNA, while the selective TGF-beta2 oligonucleotides significantly inhibit TGF-beta2 mRNA expression.

Example 3

In further experiments the inhibitory effect of each of ASPH01, ASPH03, ASPH05, ASPH17, ASPH18, ASPH22, ASPH26, ASPH27, ASPH33, ASPH36, ASPH37, ASPH41, ASPH42, ASPH45, ASPH46, ASPH47, ASPH48, ASPH49, ASPH64, ASPH65, ASPH66, ASPH69, ASPH71, ASPH80, ASPH82, ASPH88, ASPH89, ASPH90, ASPH98, ASPH99, ASPH102, ASPH105, ASPH115, ASPH121, ASPH140, ASPH153, ASPH165, ASPH171, ASPH178, ASPH181, ASPH184, ASPH185, ASPH186, ASPH187, ASPH188, ASPH189, and of the controls of SEQ ID NO.144 and SEQ ID NO. 145 was tested in human A172 glioma cells. A172 cells were transfected with these modified oligonucleotides in doses of 20 nM, 4 nM, 0.8 nM, 0.16 nM, and 0.04 nM, respectively, in the presence of a transfecting agent. The remaining TGF-beta2 mRNA was measured 24 h after transfection. TGF-beta2 values were normalized to GAPDH and oligonucleotide concentrations resulting in 50% reduction of TGF-beta2 mRNA (=IC₅₀ values) were calculated. All IC₅₀ values were referenced to the IC₅₀ value of ASPH_036 (ASPH36) that was 0.33 nM and the results are shown as fold-difference of the IC₅₀ value of ASPH_036 Table 2:

Fold IC₅₀ referenced to Oligonucleotide ASPH_036 ASPH_080 0.591 ASPH_069 0.673 ASPH_065 0.773 ASPH_105 0.882 ASPH_036 1.000 ASPH_046 1.142 ASPH_098 1.182 ASPH_071 1.237 ASPH_026 1.242 ASPH_047 1.303 ASPH_088 1.455 ASPH_185 1.456 ASPH_115 1.545 ASPH_153 1.665 ASPH_181 1.918 ASPH_027 2.000 ASPH_089 2.091 ASPH_102 2.091 ASPH_041 2.182 ASPH_018 2.212 ASPH_049 2.455 ASPH_022 2.485 ASPH_188 2.639 ASPH_189 2.660 ASPH_042 2.848 ASPH_178 3.147 ASPH_048 3.182 ASPH_066 3.182 ASPH_033 3.182 ASPH_045 3.636 ASPH_121 3.644 ASPH_171 3.871 ASPH_005 3.954 ASPH_003 4.111 ASPH_082 4.818 ASPH_037 5.303 ASPH_099 5.545 ASPH_090 6.727 ASPH_165 7.175 ASPH_186 7.655 ASPH_017 8.455 ASPH_001 9.242 ASPH_187 9.990 ASPH_064 10.091 ASPH_140 11.482 ASPH_184 12.224 SEQ ID NO 144 17.212 SEQ ID NO 145 n.a All the modified oligonucleotides show an IC₅₀ in a low nanomolar to picomolar range, which is markedly lower than IC₅₀ of the positive control oligonucleotide of SEQ ID NO. 144; the IC₅₀ of the negative control of SEQ ID NO. 145 was not calculable.

Example 4

Human Panc-1 pancreatic cancer cells were treated with 3.3 μM of ASPH17, ASPH18, ASPH22, ASPH25, ASPH33, ASPH35, ASPH36, ASPH41, ASPH42, ASPH45, ASPH46, ASPH47, ASPH48, ASPH49, ASPH65, ASPH66, ASPH67, ASPH69, ASPH71, ASPH79, ASPH80, ASPH82, ASPH88, ASPH89, ASPH90, ASPH91, ASPH98, ASPH99, ASPH102, ASPH105, ASPH111, ASPH115, ASPH119, ASPH121, ASPH139, ASPH140, ASPH146, ASPH151, ASPH153, ASPH165, ASPH171, ASPH172, ASPH176, ASPH178, ASPH180, and ASPH183, respectively, or the controls of SEQ ID NO. 144 and 145 in the absence of a transfecting agent (gymnotic transfection or gymnotic delivery). The inhibitory effect of the modified oligonucleotides on expression of TGF-beta1 and TGF-beta2 mRNA, respectively, was determined 72 h after treatment start. Under gymnotic delivery experimental conditions, the oligonucleotides enter the cells and strongly inhibit the expression of TGF-beta2 mRNA. The results of the experiments are shown in FIG. 5a and FIG. 5 b.

Example 5

In further experiments human Panc-1 pancreatic cancer cells were transfected with 10 μM of modified oligonucleotides ASPH01, ASPH03, ASPH05, ASPH09, ASPH17, ASPH18, ASPH22, ASPH35, ASPH36, ASPH37, ASPH41, ASPH45, ASPH46, ASPH47, and ASPH48, respectively, or the controls of SEQ ID NO. 144 and 145 in the absence of a transfecting agent (gymnotic transfection or gymnotic delivery). The oligonucleotides were added to the cells for 2 days, after which medium was changed, and further incubation for 2 days was carried out in oligonucleotide-containing medium. Expression of TGF-beta1 mRNA (FIG. 6a ) and TGF-beta2 mRNA (FIG. 6b ) was then measured and normalized to HPRT1 (Hypoxanthin-Phosphoribosyl-Transferase1). Cell supernatants were analysed for TGF-beta1 (FIG. 7a ) and TGF-beta2 (FIG. 7b ) protein by ELISA. Under gymnotic delivery experimental conditions, dual TGF-beta1 and TGF-beta2 reactive oligonucleotide ASPH01, ASPH03, ASPH05, and pan-specific ASPH09 significantly inhibit the expression of TGF-beta1 and TGF-beta2 mRNA, and protein. All the other oligonucleotides significantly inhibit the expression of TGF-beta2 mRNA and protein.

Example 6

In another experiment dose dependency of the inhibitory effect of modified oligonucleotides of the present invention was tested. Human Panc-1 pancreatic cancer cells were treated with 15 μM, 10 μM, 7.5 μM, 5 μM, 2.5 μM, 1.25 μM, or 0.625 μM ASPH05 or ASPH36, or the controls of SEQ ID NO. 144 and 145, respectively, without using a transfection reagent. The oligonucleotides were added to the cells for 2 days. Thereafter media were changed and cells were incubated for 2 further days in oligonucleotide-containing medium, after which (total treatment time: 4 days) the expression of TGF-beta1 (FIG. 8a ) and TGF-beta2 (FIG. 8b ) mRNA was measured. The dual TGF-beta1 and TGF-beta2 reactive oligonucleotide ASPH05 shows a marked dose dependent inhibition of both TGF-beta1 and TGF-beta2 mRNA expression, and ASPH36 inhibits specifically the expression of TGF-beta2 mRNA in a dose-dependent manner.

Example 7

Mouse SMA-560 glioma cells were transfected with 10 nM ASPH01, ASPH03, ASPH05, ASPH09, ASPH17, ASPH18, ASPH22, ASPH26, ASPH36, ASPH37, ASPH41, ASPH42, ASPH45, ASPH46, ASPH47, or ASPH48, or the controls of SEQ ID NO. 144 and 145, respectively, in the presence of a transfecting agent. 24 h after transfection, the inhibition of the expression of TGF-beta1 (white columns) and TGF-beta2 (black columns) mRNA was determined. The pan-specific ASPH09 inhibits the expression of the mouse TGF-beta1 mRNA, and the other oligonucleotides tested strongly inhibit the expression of the mouse TGF-beta2 mRNA. The results are presented in FIG. 9.

Example 8

Female athymic nude mice (Hsd: Athymic Nude-Foxn1^(nu)) were treated for 5 consecutive days with 14 mg/kg or 50 mg/kg of oligonucleotide ASPH01, ASPH03, ASPH05, ASPH17, ASPH22, ASPH37, ASPH41, ASPH45, ASPH46, ASPH47, or ASPH48, and control of SEQ ID NO. 145, respectively, or saline by subcutaneous injection. The day after the last treatment, the mice were sacrificed. Mouse TGF-beta2 mRNA was quantified in kidney tissue lysates. In FIG. 10, data—representing TGF-beta2 to GAPDH mRNA ratio—are shown as a box plot in which median values and min. and max. values are presented (data expressed as n=4, except ASPH46 group n=3). All the tested oligonucleotides inhibited the expression of TGF-beta2 mRNA in the kidney of these mice.

Example 9

In another experiment human Panc-1 pancreatic cancer cells were transfected with 10 μM of modified oligonucleotide ASPH09 or the control of SEQ ID NO. 145 in the absence of any transfecting agent (gymnotic transfection or gymnotic delivery). The oligonucleotides were added to the cells for 2 days, after medium was changed, and further incubation for 2 days was carried out in oligonucleotide-containing medium. Expression of TGF-beta3 mRNA (see FIG. 11) was then measured and normalized to HPRT 1 (Hypoxanthin-Phosphoribosyl-Transferase1). Under gymnotic delivery experimental conditions, the pan-specific oligonucleotide ASPH09 significantly inhibits the expression of TGF-beta3 mRNA.

Example 10

Human Panc-1 pancreatic cancer cells were treated with 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, and 0.12 μM of ASPH03, ASPH36, ASPH45, ASPH47, ASPH65, ASPH69, AASPH71, ASPH80, ASPH115, ASPH 121, ASPH153, ASPH185, and ASPH189, respectively, in the absence of a transfecting agent (gymnotic transfection or gymnotic delivery). The inhibitory effect of the modified oligonucleotides on expression of TGF-beta2 mRNA, was determined 72 h after treatment start. TGF-beta2 values were normalized to GAPDH and oligonucleotide concentrations resulting in 50% reduction of TGF-beta2 mRNA (=IC₅₀ values) were calculated. Under gymnotic delivery experimental conditions, the oligonucleotides enter the cells and strongly inhibit the expression of TGF-beta2 mRNA. The results of the experiments are shown in Table 3:

Name IC50 (μM) ASPH_065 0.37 ASPH_071 0.371 ASPH_115 0.6 ASPH_069 0.655 ASPH_047 0.78 ASPH_080 0.81 ASPH_153 0.9 ASPH_045 1.21 ASPH_121 1.27 ASPH_036 1.5 ASPH_185 3.05 ASPH_003 3.62 ASPH_189 4.26 All the modified oligonucleotides show an IC₅₀ in the low micromolar or even submicromolar range, showing that they have very high potency even without the requirement of a transfection reagent.

Example 11

Human Panc-1 pancreatic cancer cells were treated with 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, and 0.12 μM of ASPH47, ASPH190, ASPH191, ASPH192, and ASPH193, respectively, in the absence of a transfecting agent (gymnotic transfection or gymntic delivery). The inhibitory effect of the modified oligonucleotides on expression of TGF-beta2 mRNA, was determined 72 h after treatment start. TGF-beta2 values were normalized to GAPDH and oligonucleotide concentrations resulting in 50% reduction of TGF-beta2 mRNA (=IC₅₀ values) were calculated. Under gymnotic delivery experimental conditions, the oligonucleotides enter the cells and strongly inhibit the expression of TGF-beta2 mRNA. The results of the experiments are shown in Table 4:

Name IC50 (μM) ASPH_047 0.76 ASPH_190 0.18 ASPH_191 0.97 ASPH_192 0.145 ASPH_193 0.144 All the modified oligonucleotides show an IC₅₀ in the submicromolar to lower submicromolar range, showing that they have extremely high potency even without the requirement of a transfection reagent.

Example 12

Human Panc-1 pancreatic cancer cells were transfected with 10 nM of ASPH05, ASPH09, ASPH1000, ASPH1001, ASPH1002, ASPH1003, ASPH1004, ASPH1005, ASPH1006, ASPH 1007, ASPH1008, ASPH1009, ASPH1010, ASPH1011, ASPH1012, ASPH1013, ASPH1014, ASPH1015, ASPH1016, ASPH1017, ASPH1018, ASPH1019, ASPH1020, ASPH1021, ASPH1022, ASPH1023, ASPH1024, ASPH1026, ASPH1027, ASPH1028, ASPH1029, ASPH1030, ASPH1031, ASPH1032, ASPH1033, ASPH1034, ASPH1035, ASPH1036, ASPH 1038, ASPH1039, ASPH1040, ASPH1041, ASPH1042, ASPH1043, ASPH1044, ASPH1045, ASPH1046, ASPH1047, ASPH1048, ASPH1049, ASPH1050, ASPH1051, ASPH1052, ASPH1054, ASPH1055, ASPH1056, ASPH1057, ASPH1058, ASPH1059, ASPH1060, or ASPH1061 and the control of SEQ ID NO. 145, respectively, in the presence of a transfecting agent. The expression of TGF-beta1 mRNA was determined 24 h after transfection. Significant reduction of the expression of TGF-beta1 in Panc-1 cells is shown in FIG. 13a and FIG. 13 b.

Example 13

Mouse SMA-560 glioma cells were transfected with 10 nM of ASPH09, ASPH1000, ASPH1001, ASPH1002, ASPH1003, ASPH1004, ASPH1005, ASPH1006, ASPH1007, ASPH1008, ASPH1009, ASPH1010, ASPH1011, ASPH1012, ASPH1013, ASPH1014, ASPH1015, ASPH1016, ASPH1017, ASPH1018, ASPH1019, ASPH 1020, ASPH1021, ASPH1022, ASPH1023, ASPH1024, ASPH1026, ASPH1027, ASPH1028, ASPH1029, ASPH1030, ASPH1031, ASPH1032, ASPH1033, ASPH1034, ASPH1035, ASPH1036, ASPH1037, ASPH1038, ASPH1039, ASPH1040, ASPH1041, ASPH1042, ASPH1043, ASPH1044, ASPH1045, ASPH1046, ASPH1047, ASPH1048, ASPH1049, ASPH1050, ASPH1051, ASPH1052, ASPH1053, ASPH1054, ASPH1055, ASPH1056, ASPH1057, ASPH1058, ASPH1059, ASPH1060, ASPH1061, or ASPH1062 and the control of SEQ ID NO. 145, respectively, in the presence of a transfecting agent. The expression of TGF-beta1 mRNA was determined 24 h after transfection. Significant reduction of the expression of TGF-beta1 in SMA-560 cells is shown in FIG. 14.

Example 14

In these experiments, human A172 glioma cells were transfected with 10 nM of ASPH05, ASPH09, ASPH1000, ASPH1001, ASPH1002, ASPH1004, ASPH1005, ASPH1006, ASPH1007, ASPH1008, ASPH1009, ASPH1010, ASPH1011, ASPH1012, ASPH1013, ASPH1014, ASPH1015, ASPH1016, ASPH1017, ASPH1018, ASPH1019, ASPH1020, ASPH1021, ASPH1022, ASPH1023, ASPH1024, ASPH1026, ASPH1027, ASPH1028, ASPH1029, ASPH1030, ASPH1031, ASPH1032, ASPH1033, ASPH1034, ASPH1035, ASPH1036, ASPH1038, ASPH1039, ASPH1040, ASPH1041, ASPH1042, ASPH1043, ASPH1044, ASPH1045, ASPH1046, ASPH1047, ASPH1048, ASPH1049, ASPH1050, ASPH1051, ASPH1052, ASPH1053, ASPH1054, ASPH1056, ASPH1057, ASPH1058, ASPH1059, ASPH1060, ASPH1061, or ASPH1062, and the control of SEQ ID NO. 145, respectively, in the presence of a transfecting agent. The expression of TGF-beta1 and TGF-beta2 mRNA was determined 24 h after transfection. Significant reduction of the expression of TGF-beta1 mRNA is shown in FIG. 15a , FIG. 15b , and FIG. 15c . The dual TGF-beta1 and TGF-beta2 reactive oligonucleotides ASPH05 shows a significant reduction of the expression of both TGF-beta1 and TGF-beta2 mRNAs, while the selective TGF-beta1 oligonucleotides significantly inhibit TGF-beta1 mRNA expression.

Example 15

Human Panc-1 pancreatic cancer cells were treated with 3.3 μM of ASPH05, ASPH09, ASPH1000, ASPH1001, ASPH1002, ASPH1004, ASPH1006, ASPH1007, ASPH1008, ASPH1009, ASPH1010, ASPH1011, ASPH1012, ASPH1013, ASPH1014, ASPH1015, ASPH1017, ASPH1018, ASPH1019, ASPH1020, ASPH1021, ASPH1022, ASPH1024, ASPH1026, ASPH1027, ASPH1028, ASPH1029, ASPH1032, ASPH1033, ASPH1034, ASPH1035, ASPH1036, ASPH1037, ASPH1038, ASPH1039, ASPH1040, ASPH1041, ASPH1042, ASPH1043, ASPH1044, ASPH1045, ASPH1046, ASPH1047, ASPH1049, ASPH1050, ASPH1051, ASPH1052, ASPH1053, ASPH1054, ASPH1055, ASPH1056, ASPH1057, ASPH1058, ASPH1059, ASPH1060, ASPH1061, or ASPH1062, or the control of SEQ ID NO. 145 in the absence of a transfecting agent (gymnotic transfection or gymnotic delivery). The inhibitory effect of the modified oligonucleotides on expression of TGF-beta1 and TGF-beta2 mRNA, respectively, was determined 72 h after treatment start. Significant reduction of the expression of TGF-beta1 mRNA is shown in FIG. 16a , FIG. 16b . and FIG. 16c . The dual TGF-beta1 and TGF-beta2 reactive oligonucleotides ASPH05 shows a significant reduction of the expression of both TGF-beta1 and TGF-beta2 mRNAs, while the selective TGF-beta1 oligonucleotides significantly inhibit TGF-beta1 mRNA expression.

Example 16

Human A172 glioma cells were treated with 10 nM (in the presence of a transfecting agent), of ASPH09, ASPH1047, ASPH1051, ASPH1059, ASPH1063, ASPH1064, ASPH1065, ASPH1066, ASPH1067, ASPH1068, ASPH1069, ASPH1070, ASPH1071, ASPH1072, ASPH1073, ASPH1074, ASPH1075, ASPH1076, ASPH1077, ASPH1078, ASPH1079, ASPH1080, ASPH1081, ASPH1082, ASPH1083, ASPH1084, ASPH1085, ASPH1086, ASPH1087, ASPH1088, ASPH1089, ASPH1090, ASPH1091, ASPH1092, ASPH1093, ASPH1094, ASPH1095, ASPH1097, ASPH1098, ASPH1099, ASPH1100, ASPH1101, ASPH1102, ASPH1103, ASPH1104, ASPH1105, ASPH1106, ASPH1107, ASPH1108, ASPH1109, ASPH1110, ASPH1111, ASPH1112, ASPH1113, ASPH114, ASPH1115, ASPH1116, ASPH1117, ASPH1118, ASPH1119, ASPH1120, ASPH1121, ASPH1122, ASPH1123, ASPH1124, ASPH1125, ASPH1126, ASPH1127, ASPH1128, ASPH1129, ASPH1130, ASPH1131, and ASPH1132, respective1, or the positive control ASPH1047. The expression of TGF-beta1 (black column), TGF-beta2 (white column) and TGF-beta3 (striped column) mRNA was determined 24 h after transfection. Significant reduction of the expression of TGF-beta1 mRNA is shown in FIG. 17. The pan-specific TGF-beta1, TGF-beta2 and TGF-beta3 reactive oligonucleotides ASPH0009, ASPH1096, ASPH1131, and ASPH1132 show a significant reduction of the expression of all three isoforms, while the selective TGF-beta1 oligonucleotides significantly inhibit TGF-beta1 mRNA expression.

Example 17

Either human Panc-1 pancreatic cancer cells (FIG. 18a (i), and FIG. 18a (ii) or mouse RenCa renal cell carcinoma cells (FIG. 18a (i), and FIG. 18a (ii)) were treated with 3.3 μM of ASPH09, ASPH1047, ASPH1051, ASPH1059, ASPH1063, ASPH1064, ASPH1065, ASPH1066, ASPH1067, ASPH1068, ASPH1069, ASPH1070, ASPH1071, ASPH1072, ASPH1073, ASPH1074, ASPH1075, ASPH1076, ASPH1077, ASPH1078, ASPH1079, ASPH1080, ASPH1081, ASPH1082, ASPH1083, ASPH1084, ASPH1085, ASPH1086, ASPH1087, ASPH1088, ASPH1089, ASPH1090, ASPH1091, ASPH1092, ASPH1093, ASPH1094, ASPH1095, ASPH1097, ASPH1098, ASPH1099, ASPH1100, ASPH1101, ASPH1102, ASPH1103, ASPH1104, ASPH1105, ASPH1106, ASPH1107, ASPH1108, ASPH1109, ASPH1110, ASPH1111, ASPH1112, ASPH1113, ASPH114, ASPH1115, ASPH1116, ASPH1117, ASPH1118, ASPH1119, ASPH1120, ASPH1121, ASPH1122, ASPH1123, ASPH1124, ASPH1125, ASPH1126, ASPH1127, ASPH1128, ASPH1129, ASPH1130, ASPH1131, and ASPH1132, respectively, or the positive control ASPH1047 in the absence of a transfecting agent (gymnotic transfection or gymnotic delivery). The expression of TGF-beta1 (black column), TGF-beta2 (white column) and TGF-beta3 (striped column) mRNA was determined 72 h after transfection. Significant reduction of the expression of TGF-beta1 mRNA is shown in FIG. 17. The pan-specific TGF-beta1, TGF-beta2 and TGF-beta3 reactive oligonucleotides ASPH0009, ASPH1096, ASPH1131, and ASPH1132 show significant reduction of the expression of all three isoforms, while the selective TGF-beta1 oligonucleotides significantly inhibit TGF-beta1 mRNA expression.

Example 18

Mice bearing human Panc-1 pancreatic carcinoma subcutaneous tumors were treated with 1, 3, 10, and 30 mg/kg of ASPH47 under various treatment schedules: Q1Dx1-d6 (single SC injection, termination 5 days later), Q1Dx5-d6 (daily SC injection for 5 days, termination 24 hours later), and Q1Dx5-d10 (daily SC injection for 5 days, termination 5 days later). There was a dose dependent down-regulation of TGF-beta2 mRNA in the kidney of these animals. TGF-beta2 down-regulation was persistent up to 5 days after the last treatment with ASPH47, even after only single administration. TGF-beta2 expression was detected by bDNA assay (branched DNA assay, which is a sandwich nucleic acid hybridization method that uses bDNA molecules to amplify signal from captured target RNA) and normalized to GAPDH. As shown in FIG. 22, data—representing TGF-beta2 to GAPDH mRNA ratio—are shown as a box plot in which median values and min. and max. values are presented (data expressed as n=10, except n=9 for vehicle and 3 mg/kg Q1Dx1 d6 groups).

Example 19

Mice bearing human Panc-1 pancreatic carcinoma subcutaneous tumors on both left and right flanks were treated with a daily subcutaneous injection of 1, 5, 15 or 50 mg/kg oligonucleotides for five consecutive days. The tumors were collected 24 hours after the last treatment and snap frozen. TGF-beta mRNA expression in tumors was detected by bDNA assay. Data—representing TGF-beta2 to GAPDH mRNA ratio—are shown as a box plot in which median values and min. and max. values are presented (data expressed as n=5). TGF-beta2 mRNA was down-regulated in tumors treated with various oligonucleotides (FIG. 23). There was no significant TGF-beta1 mRNA down-regulation in those groups (data not shown).

Example 20

Mice bearing human 786-O renal cell carcinoma subcutaneous tumors on both left and right flanks were treated with a daily injection of 50 mg/kg oligonucleotides for five consecutive days. The tumors were collected 24 hours after the last treatment and snap frozen. TGF-beta mRNA expression in tumors was detected by bDNA assay. There was significant down-regulation of TGF-beta2 mRNA in tumors treated with ASPH05, ASPH17, ASPH26, ASPH36, ASPH45, ASPH47, ASPH71, ASPH82, ASPH98, and ASPH105 (FIG. 24). Data—representing TGF-beta2 to GAPDH mRNA ratio—are shown as a box plot in which median values and min. and max. values are presented (data expressed as n=10, except for ASPH71 group n=9).

Example 21

Human Panc-1 pancreatic cancer cells were transfected with 20, 6.67, 2.22, 0.74, 0.25, 0.08 or 0.009 μM of the modified oligonucleotides ASPH47, ASPH1047, ASPH1106, ASPH1132, or ASPH47 in combination with ASPH1047; results are shown in FIG. 26a to 26e ). Negative control is the scrambled oligonucleotide (scrLNA) of SEQ ID No. 145 (FIG. 26f ). All cells were transfected in the absence of transfecting agent (gymnotic transfection or gymnotic delivery). The modified oligonucleotides were added to the cells for 3 days, which were incubated at 37° C. Thereafter medium was exchanged with fresh oligonucleotide containing medium and cells were incubated for further 4 days at 37° C. TGF-beta1 and TGF-beta2 protein levels in cell supernatants were determined by ELISA. ASPH47 specifically inhibits the expression of TGF-beta2 in a dose-dependent manner and does not have any target inhibiting effect on TGF-beta1 (FIG. 26a ). ASPH1047 specifically inhibits the expression of TGF-beta1 and does not have any target inhibiting effect on TGF-beta2 (FIG. 26b ), or only a slight TGF-beta2 inhibiting effect at higher concentrations. Also ASPH1106 inhibits TGF-beta1 expression in a dose dependent manner (FIG. 26c ). The pan-specific ASPH 1132 shows a dose-dependent inhibition of the expression of TGF-beta1 and TGF-beta2 protein (FIG. 26d ). When ASPH47 and ASPH1047 are combined, the expression of both, TGF-beta1 and TGF-beta2 protein is inhibited in a dose dependent manner (FIG. 26e ). The scrLNA of SEQ ID No. 145 does not show any inhibiting effect on the expression of neither TGF-beta1 nor TGF-beta2, even if the concentrations were doubled (40, 13.33, 4.44, 1.48, 0.49, 0.16, 0.05, or 0.02 μM) in comparison to the individual concentrations of ASPH47, ASPH1047, ASPH1106, or ASPH1132. Results for TGF-beta1 are indicated in diamonds, and results for TGF-beta2 in squares in FIG. 26a , FIG. 26b , FIG. 26c , FIG. 26d , FIG. 26e , FIG. 26 f.

Example 22

Human Panc-1 pancreatic cancer cells (FIG. 27a ) or mouse RenCa renal cell carcinoma cells (FIG. 27b ) were treated with 3.3 μM of ASPH0009, ASPH1132, ASPH2000, ASPH2001, ASPH2002, ASPH2003, ASPH2004, ASPH2005, ASPH2006, ASPH2007, ASPH2009, ASPH2010, ASPH2012, ASPH2013, ASPH2014 ASPH2015, ASPH2016, ASPH2017, ASPH2018, ASPH2019, ASPH2020, ASPH2021, ASPH2023, ASPH2024, ASPH2025, ASPH23026, ASPH2027, ASPH2028, ASPH2029, ASPH2030, ASPH2031, ASPH2032, ASPH2033, ASPH2034, ASPH2035, ASPH2036, ASPH2037, ASPH2038, ASPH2039, ASPH2040, ASPH2041, ASPH2043, ASPH2044, ASPH2045, ASPH2046, ASPH2047, ASPH2048, ASPH2049, ASPH2050, ASPH2052, ASPH2053, ASPH2054, ASPH2055, ASPH2056, ASPH2057, ASPH2060, ASPH2061, ASPH2062, ASPH2063, ASPH2064, ASPH2065, or ASPH2066 in the absence of a transfecting agent (gymnotic transfection or gymnotic delivery). The expression of TGF-beta1 (black column), TGF-beta2 (white column) and TGF-beta3 (striped column) mRNA was determined 72 h after transfection. Significant reduction of the expression of TGF-beta3 mRNA is shown in FIG. 27a and FIG. 27b . As anticipated from the sequences, the TGF-beta1, -beta2 and -beta3 reactive oligonucleotide ASPH 0009 (pan-selective) and ASPH_1132 that has 100% homology to mRNAs of human TGF-beta1 and -beta3 but has a mismatch to TGF-beta2 show significant reduction of the expression of all three isoforms. The selective TGF-beta3 oligonucleotides only significantly inhibit TGF-beta3 mRNA expression.

Example 23

Human A172 glioma cells were treated for 24 h with 10 nM (in the presence of a transfecting agent), of ASPH0009, ASPH1132, ASPH2000, ASPH2001, ASPH2002, ASPH2003, ASPH2004, ASPH2006, ASPH2007, ASPH2008, ASPH2009, ASPH2010, ASPH2011, ASPH2012, ASPH2013, ASPH2014, ASPH2016, ASPH2017, ASPH2018, ASPH2020, ASPH2021, ASPH2022, ASPH2023, ASPH2024, ASPH2025, ASPH2026, ASPH2027, ASPH2028, ASPH2029, ASPH2030, ASPH2031, ASPH2032, ASPH2033, ASPH2034, ASPH2035, ASPH2036, ASPH2037, ASPH2038, ASPH2039, ASPH2040, ASPH2041, ASPH2042, ASPH2043, ASPH2044, ASPH2045, ASPH2047, ASPH2049, ASPH2050, ASPH2051, ASPH2052, ASPH2053, ASPH2054, ASPH2056, ASPH2057, ASPH2058, ASPH2059, ASPH2060, ASPH2061, ASPH2062, ASPH2063, or ASPH2066. The expression of TGF-beta1 (black column), TGF-beta2 (white column) and TGF-beta3 (striped column) mRNA was then determined from cell extracts by bDNA assay. Significant reduction of the expression of TGF-beta3 mRNA is shown in FIG. 28. As anticipated from the sequences, the TGF-beta1, -beta2 and -beta3 reactive oligonucleotide) ASPH_0009 (pan-selective) and ASPH_1132 that has 100% homology to mRNAs of human TGF-beta1 and -beta3 but has a mismatch to TGF-beta2 show significant reduction of the expression of all three isoforms. The selective TGF-beta3 oligonucleotides only significantly inhibit TGF-beta3 mRNA expression.

Example 24

Target mRNA downregulation in rabbit cells Sequences of selected oligonucleotides were aligned with rabbit mRNA sequences of TGF-beta1 and 2. ASPH 0036 (TGF-beta2 selective antisense oligonucleotide, based on human mRNA sequence) showed 100% homology with rabbit TGF-beta2 mRNA, while ASPH 1059 (TGF-beta1 selective antisense oligonucleotide, based on human mRNA sequence) showed 100% homology with rabbit TGF-beta1 mRNA.

Rabbit Rab-9 skin fibroblasts were treated with 5 nM or 20 nM of either ASPH_0036 and ASPH_1059 in the presence of a transfecting agent for 24 hr. The expression of TGF-beta1 and TGF-beta2 mRNA was then determined in cell extracts by bDNA assay. Significant reduction of the expression of TGF-beta1 mRNA (51 and 77% at 5 and 20 nM, respectively) was achieved with ASPH 1059. Significant reduction of TGF-beta2 mRNA (79 and 80% at 5 and 20 nM, respectively) was achieved with ASPH_0036.

Example 25

Tissue biodistribution and target mRNA downregulation following systemic administration of ASPH_0047 in Balb/c mice.

Balb/C mice were treated with a single subcutaneous injection of ASPH_0047 (formulated in sterile physiological saline) at 5, 20 and 50 mg/kg animal body weight. Plasma and tissues were collected at the indicated times (from 3 individual animals), immediately snap-frozen and stored at −80° C. until analysis with an AEX-HPLC method (plasma/tissue PK) or for measurement of TGF-β2 and GAPDH mRNA levels by bDNA assay. TGF-β2 mRNA levels were expressed relative to GAPDH mRNA expression level in corresponding samples.

The data depict that a single subcutaneous bolus administration of 50 mg/kg ASPH_0047 resulted in rapid transfer of the drug from subcutaneous to circulating blood compartments (T_(MAX) of ˜5-30 min), biphasic pharmacokinetic profile in plasma, with rapid initial elimination phase (within the first 24 hrs), followed by long terminal half-life (FIG. 29a ). It is further demonstrated that a marked long-lasting accumulation of the drug in various selected tissues. The major target organ (highest exposure/C_(MAX)) is the kidney, then the liver, skin and spleen, and lowest in the brain (data not shown). As also depicted in FIG. 29b , ASPH_0047 remained in the kidney tissue with pharmacological relevant doses (˜50 μg/gr, equivalent to 10 μM) from 24 h and for up to 14 days, with consequent long-lasting and marked suppression of TGF-β2 mRNA expression in the kidney tissue, with effective ˜80% target mRNA downregulation observed for at least 14 days.

Example 26

Immunodeficient mice were injected subcutaneously with human 786-O renal cell carcinoma cells (FIG. 30A), pancreatic Panc1 cancer cells (FIG. 30B, C), or mouse SMA-560 glioma cells (FIG. 30D). When subcutaneous tumors reached the size of 100-300 mm³ (established tumors), animals were treated subcutaneously, QDx5, with saline (Mock), control oligonucleotide (Control; 50 mg/kg), inactive oligonucleotides in this context (e.g., ASPH_0065 and ASPH_0071; 50 mg/kg) or ASPH_0047 at 50 mg/kg, or the indicated doses. Tumors (FIG. 30A-D) and kidneys (FIG. 30E-F) were collected 24 hr after the last administration. Tumors/kidneys were then further processed for determination of TGF-□2 and GAPDH mRNA levels by bDNA assay. In these experiments, control oligonucleotide was a 18-mer, 3+3 LNA gapmer scrambled sequence. Results are expressed as TGF-beta2/GAPDH mRNA ratio, and each individual tested sample is represented with median values indicated as red line. Under described experimental conditions (schedule and route of administration), systemic repeated administrations of ASPH 0047 in Balb/c mice led to a sequence-specific downregulation of TGF-beta 2 mRNA in established subcutaneous tumors and kidneys.

Example 27

Balb/c mice were injected with mouse Renca cells into renal subcapsule (FIG. 31A, B) or i.v. (FIG. 31C, D) on Day 0. Systemic treatment with vehicle or indicated oligonucleotides started on Day 7 (FIG. 31A; 50 mg/kg, s.c., twice weekly), on Day 1 (FIG. 31B; 12.5 mg/kg, s.c., twice weekly) for two consecutive weeks, or on Day 7 (FIGS. 31C and 31D; indicated doses, s.c., twice weekly) for 26-27 days. Number of lung metastasis was macroscopically evaluated, and level of lung metastasis was determined by either number of metastasis (FIG. 31A, C) or based on lung weight (FIG. 31B, D). Results are represented as box plot; with median values, upper and lower quartiles, and 90th and 10th percentiles. Under described experimental designs, Balb/c mice treated with ASPH_0047 showed a reduced number of lung metastasis or reduced lung weight (lung weight correlates to extent of lung metastasis) in mouse Renca RCC models.

Example 28

Human Panc-1 pancreatic cancer cells were treated with 3.3 μM of the indicated oligonucleotides in the absence of transfecting agent (gymnotic transfection or gymnotic delivery). The expression of TGF-beta1 (black column), TGF-beta2 (white column) and TGF-beta3 (striped column) mRNA was determined 72 h after transfection. Significant reduction of the expression of TGF-beta1 mRNA is shown in FIG. 32. The selective TGF-beta1 oligonucleotides only significantly inhibit TGF-beta1 mRNA expression while the control oligonucleotide LNA-scr does not affect expression of any TGF-beta isoform.

Example 29

Balb/c mice were injected with mouse 4T1 cells into mammary fat pad on Day 0. Systemic treatment with saline (Mock), pan-TGF-beta antibody (1D11), control oligonucleotide (LNA-scr), or ASPH_0047 started on Day 3 (30 mg/kg, s.c., twice weekly) and continued until D28, when animals were sacrificed. Number of lung metastasis was macroscopically evaluated, and level of lung metastasis was determined by either number of metastasis (left panel) or based on lung weight (right panel).

Example 30

CB17 SCID or Balb/c nude mice (n=3-5, except ASPH 0018 n=1 and ASPH_0037 n=2) were treated with 14-15 mg/kg of indicated LNA-modified oligonucleotides for four or five consecutive days (Q1Dx4-5). Plasma was collected 24 h after the last treatment and ALT levels were determined. Results are expressed as median. The following Table 7 shows liver toxicity of systemically administered LNA-modified oligonucleotides:

ALT ALT Name (units/l) Name (units/l) ASPH_0001 20.5 ASPH_0115 985.5 ASPH_0003 20.0 ASPH_0190 902.0 ASPH_0005 33.0 ASPH_0191 36.5 ASPH_0009 834.0 ASPH_0192 49.5 ASPH_0017 55.0 ASPH_0193 35.0 ASPH_0018 7723.0 ASPH_0005_C1 25.5 ASPH_0022 28.5 ASPH_0005_C2 35.5 ASPH_0026 77.0 ASPH_0005_C3 25.0 ASPH_0027 75.0 ASPH_0036_C1 34.0 ASPH_0035 25.0 ASPH_0036_C2 26.0 ASPH_0036 131.5 ASPH_0036_C3 39.0 ASPH_0037 161.0 ASPH_0045_C1 38.5 ASPH_0041 655.0 ASPH_0045_C2 23.5 ASPH_0045 27.5 ASPH_0045_C3 65.0 ASPH_0046 3199.0 ASPH_0047_C1 35.5 ASPH_0047 42.5 ASPH_0047_C2 30.0 ASPH_0048 29.5 ASPH_0047_C3 29.5 ASPH_0065 27.0 ASPH_0047_C4 52.5 ASPH_0069 32.5 ASPH_0047_C5 28.0 ASPH_0071 23.5 ASPH_0047_C6 33.5 ASPH_0080 34.0 ASPH_0047_C7 37.0 ASPH_0082 31.0 ASPH_0047_C8 32.0 ASPH_0098 33.0 ASPH_0047_C9 49.0 ASPH_0105 40.0 ASPH_0047_C10 32.5

EMBODIMENTS

1. Oligonucleotide consisting of 12 to 18 nucleotides of the TGF-beta2 nucleic acid sequence of SEQ ID NO. 1, wherein one or more nucleotide(s) of the oligonucleotide is/are a LNA modified, wherein the modified nucleotide is a LNA, and/or an ENA, polyalkylene oxide-, 2′-fluoro-, 2′-O-methoxy-, and/or 2′O-methyl-modified nucleotide. 2. Oligonucleotide according to embodiment 1 consisting of 12 to 18 nucleotides of the region of nucleic acid no. 1380 to 1510, no. 1660 to 1680, no. 2390 to 2410, or no. 2740 to 2810 of the TGF-beta2 nucleic acid sequence of SEQ ID NO. 1. 3. Oligonucleotide according to any one of embodiments 1 or 2, wherein the modified nucleotide is located at the 5′- and/or 3′-end of the oligonucleotide. 4. Oligonucleotide according to any one of embodiments 1 to 3, wherein the oligonucleotide comprises a sequence selected from the group consisting of SEQ ID NO. 46, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO.17, SEQ ID NO. 18, SEQ ID NO. 25, SEQ ID NO. 31, SEQ ID NO. 35, SEQ ID NO. 44, SEQ ID NO. 47, SEQ ID NO. 57, SEQ ID NO. 61, SEQ ID NO. 63, SEQ ID NO. 73, SEQ ID NO. 95, and SEQ ID NO. 103. 5. Oligonucleotide according to embodiment 1 or 4, wherein the oligonucleotide is selected from the group consisting of CAAAGTATTTGGTCTCC (ASPH47), ACCTCCTTGGCGTAGTA (ASPH01), ACCTCCTTGGCGTAGTA (ASPH02), CCTCCTTGGCGTAGTA (ASPH03), CCTCCTTGGCGTAGTA (ASPH04), CTCCTTGGCGTAGTA (ASPH05), CTCCTTGGCGTAGTA (ASPH06), CTCCTTGGCGTAGTA (ASPH07), TCCTTGGCGTAGTA (ASPH08), CAGAAGTTGGCAT (ASPH09), CAGAAGTTGGCAT (ASPH10), CTGCCCGCGGAT (ASPH15), TCTGCCCGCGGAT (ASPH17), TCGCGCTCGCAGGC (ASPH22), GGATCTGCCCGCGGA (ASPH26), GGATCTGCCCGCGGA (ASPH27), CGATCCTCTTGCGCAT (ASPH30), GGCGGGATGGCAT (ASPH35), GACCAGATGCAGGA (ASPH36), CTTGCTCAGGATCTGCC (ASPH37), TCTGTAGGAGGGC (ASPH45), CCTTAAGCCATCCATGA (ASPH48), TCTGAACTAGTACCGCC (ASPH65), TACTATTATGGCATCCC (ASPH69), AGCGTAATTGGTCATCA (ASPH71), GCGACCGTGACCAGAT (ASPH80), AACTAGTACCGCCTTT (ASPH82), GCGCGACCGTGACC (ASPH98), ACCACTAGAGCACC (ASPH105), AGCGCGACCGTGA (ASPH111), GGATCGCCTCGAT (ASPH112), CTAGTACCGCCTT (ASPH115), CCGCGGATCGCC (ASPH119), GACCGTGACCAGAT (ASPH121), GACCGTGACCAGAT (ASPH153). 6. Pharmaceutical composition comprising the oligonucleotide according to any one of embodiments 1 to 5 and a pharmaceutically acceptable carrier. 7. Oligonucleotide according to any one of embodiments 1 to 5 or pharmaceutical composition according to claim 6 for use in a method of preventing and/or treating a malignant and/or benign tumor, fibrosis, cirrhosis, scleroderma or related dermatologic diseases, or a CNS disease. 8. Oligonucleotide or pharmaceutical composition for use according to embodiment 7, wherein the tumor is selected from the group consisting of solid tumors, blood born tumors, leukemias, tumor metastasis, hemangiomas, acoustic neuromas, neurofibromas, trachomas, pyogenic granulomas, psoriasis, astrocytoma, acoustic neuroma, blastoma, Ewing's tumor, craniopharyngloma, ependymoma, medulloblastoma, glioma, hemangloblastoma, Hodgkins-lymphoma, medullablastoma, leukaemia, mesothelioma, neuroblastoma, neurofibroma, non-Hodgkins lymphoma, pinealoma, retinoblastoma, sarcoma, seminoma, trachomas, Wilm's tumor, or is selected from the group of bile duct carcinoma, bladder carcinoma, brain tumor, breast cancer, bronchogenic carcinoma, carcinoma of the kidney, cervical cancer, choriocarcinoma, choroidcarcinoma, cystadenocarcinome, embryonal carcinoma, epithelial carcinoma, esophageal cancer, cervical carcinoma, colon carcinoma, colorectal carcinoma, endometrial cancer, gallbladder cancer, gastric cancer, head cancer, liver carcinoma, lung carcinoma, medullary carcinoma, neck cancer, non-small-cell bronchogenic/lung carcinoma, ovarian cancer, pancreas carcinoma, papillary carcinoma, papillary adenocarcinoma, prostate cancer, small intestine carcinoma, prostate carcinoma, rectal cancer, renal cell carcinoma, retinoblastoma, skin cancer, small-cell bronchogenic/lung carcinoma, squamous cell carcinoma, sebaceous gland carcinoma, testicular carcinoma, and uterine cancer. 

What is claimed is:
 1. A method of inhibiting and/or treating a malignant and/or a benign tumor, fibrosis, cirrhosis, scleroderma or a related dermatologic disease, or a CNS disease comprising administering an oligonucleotide to a subject in need thereof, wherein one or more nucleotide(s) of the oligonucleotide is/are LNA modified nucleotides, wherein the modified nucleotide is a LNA, and/or an ENA, polyalkylene oxide-, 2′-fluoro-, 2′-O-methoxy-, and/or 2′O-methyl-modified nucleotide; wherein said oligonucleotide is GTCTTGCAGGTGGA (SEQ. ID. NO. 252), wherein nucleotides in bold letters are LNA, and wherein the malignant and/or benign tumor, fibrosis, cirrhosis, scleroderma or related dermatologic disease, or CNS disease is at least one of solid tumors, blood born tumors, leukemia, tumor metastasis, hemangiomas, acoustic neuromas, neurofibromas, trachomas, pyogenic granulomas, psoriasis, astrocytoma, acoustic neuroma, blastoma, Ewing's tumor, craniopharyngioma, ependymoma, medulloblastoma, glioma, hemangioblastoma, Hodgkins-lymphoma, leukaemia, mesothelioma, neuroblastoma, neurofibroma, non-Hodgkins lymphoma, pinealoma, retinoblastoma, sarcoma, seminoma, trachomas, Wilm's tumor, bile duct carcinoma, bladder carcinoma, brain tumor, breast cancer, bronchogenic carcinoma, carcinoma of the kidney, cervical cancer, choriocarcinoma, choroidcarcinoma, cystadenocarcinoma, embryonal carcinoma, epithelial carcinoma, esophageal cancer, cervical carcinoma, colon carcinoma, colorectal carcinoma, endometrial cancer, gallbladder cancer, gastric cancer, liver carcinoma, lung carcinoma, medullary carcinoma, neck cancer, non-small-cell bronchogenic/lung carcinoma, ovarian cancer, pancreas carcinoma, papillary carcinoma, papillary adenocarcinoma, prostate cancer, small intestine carcinoma, prostate carcinoma, rectal cancer, renal cell carcinoma, skin cancer, small-cell bronchogenic/lung carcinoma, squamous cell carcinoma, sebaceous gland carcinoma, testicular carcinoma, or uterine cancer.
 2. A method of inhibiting and/or treating a malignant and/or a benign tumor, fibrosis, cirrhosis, scleroderma or a related dermatologic disease, or a CNS disease comprising: administering an oligonucleotide to a subject in need thereof, wherein one or more nucleotide(s) of the oligonucleotide is/are LNA modified, wherein the modified nucleotide(s) is/are a LNA and/or an ENA, polyalkylene oxide-, 2′-fluoro-, 2′-O-methoxy-, and/or 2′O-methyl-modified nucleotide; and wherein said oligonucleotide is GTCTTGCAGGTGGA (SEQ ID NO. 252; ASPH1106) wherein nucleotides in bold letters are LNA.
 3. The method according to claim 2, wherein the tumor is at least one of solid tumors, blood born tumors, leukemia, tumor metastasis, hemangiomas, acoustic neuromas, neurofibromas, trachomas, pyogenic granulomas, psoriasis, astrocytoma, acoustic neuroma, blastoma, Ewing's tumor, craniopharyngloma, ependymoma, medulloblastoma, glioma, hemangloblastoma, Hodgkins-lymphoma, medullablastoma, leukaemia, mesothelioma, neuroblastoma, neurofibroma, non-Hodgkins lymphoma, pinealoma, retinoblastoma, sarcoma, seminoma, trachomas, Wilm's tumor, or wherein the malignant and/or a benign tumor, fibrosis, cirrhosis, scleroderma or related dermatologic disease, or CNS disease is at least one of bile duct carcinoma, bladder carcinoma, brain tumor, breast cancer, bronchogenic carcinoma, carcinoma of the kidney, cervical cancer, choriocarcinoma, choroidcarcinoma, cystadenocarcinome, embryonal carcinoma, epithelial carcinoma, esophageal cancer, cervical carcinoma, colon carcinoma, colorectal carcinoma, endometrial cancer, gallbladder cancer, gastric cancer, head cancer, liver carcinoma, lung carcinoma, medullary carcinoma, neck cancer, non-small-cell bronchogenic/lung carcinoma, ovarian cancer, pancreas carcinoma, papillary carcinoma, papillary adenocarcinoma, prostate cancer, small intestine carcinoma, prostate carcinoma, rectal cancer, renal cell carcinoma, retinoblastoma, skin cancer, small-cell bronchogenic/lung carcinoma, squamous cell carcinoma, sebaceous gland carcinoma, testicular carcinoma, or uterine cancer.
 4. A method of inhibiting and/or treating tumor, fibrosis, cirrhosis, scleroderma or a related dermatologic disease, or a CNS disease comprising: administering an oligonucleotide to a subject in need thereof, wherein one or more nucleotide(s) of the oligonucleotide is/are LNA modified, wherein the modified nucleotide(s) is/are a LNA and/or an ENA, polyalkylene oxide, 2′-fluoro-, 2′-O-methoxy-, and/or 2′O-methyl-modified nucleotide; and wherein said oligonucleotide is GTCTTGCAGGTGGA (SEQ ID NO. 252) wherein nucleotides in bold letters are LNA.
 5. A method of inhibiting and/or treating a malignant and/or a benign tumor, fibrosis, cirrhosis, scleroderma or a related dermatologic disease, or a CNS disease comprising: administering an oligonucleotide to a subject in need thereof, wherein one or more nucleotide(s) of the oligonucleotide is/are modified, wherein the modified nucleotide(s) is/are a LNA and/or an ENA, polyalkylene oxide-, 2′-fluoro-, 2′-O-methoxy-, and/or 2′O-methyl-modified nucleotide; and wherein said oligonucleotide is GTCTTGCAGGTGGA (SEQ ID NO. 252; ASPH1106) wherein nucleotides in bold letters are LNA. 